September 25, 2023

Lantern Pharma Inc., an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, announced the dosing of the first patient in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-184 in patients with advanced solid tumors.

September 21, 2023

Osteal Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new category of combination therapies for orthopedic infections, announced the completion of an oversubscribed $23 million Series C equity financing. The proceeds leave Osteal well-funded to submit its New Drug Application (NDA) submission to FDA and accelerate preparation for commercial launch of VT-X7, its lead therapy for the treatment of periprosthetic joint infection (PJI)

September 19, 2023

Colossal Biosciences, the world’s first de-extinction company, and BioRescue, a consortium initiating and leading the scientific rescue mission of the northern white rhino employing advanced assisted reproduction technologies and stem cell associated techniques, have teamed up to save the northern white rhino from extinction. The partnership will also develop a roadmap for future rescue missions of endangered species using the world leading expertise of both organizations. Together they will work to improve, develop, and implement strategies in the fields of wildlife conservation research and wildlife veterinary medicine, providing approaches to reduce the sixth mass extinction.

September 19, 2023

ReCode Therapeutics, a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, announced the closing of an extension to its Series B financing, raising an additional $50 million.

September 18, 2023

Lantern Pharma Inc., an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-284. LP-284 is being developed for the treatment of relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymphoma (MCL) and double hit lymphoma (DHL) and other high-grade B-cell lymphomas (HGBL).

September 18, 2023

Leading the charge to revolutionize the prescription drug industry, Select Health announced that it is one of the first health plans in the United States to provide member access to Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs). This landmark collaboration grants Select Health members direct access to Cuban’s groundbreaking prescription drug service.

September 7, 2023

NemaLife, a TechBio company specializing in microfluidics, AI and nematode-based screening proudly announces the filing of a provisional patent application on an innovative microfluidic in vivo bioassay for identifying ingredients that improve gut health. This groundbreaking invention is set to transform the way we understand and enhance gut health, addressing critical issues related to leaky gut syndrome caused by aging, poor nutrition, and enteropathogenic infections.

September 6, 2023

Lupin Limited (Lupin) forged a unique collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs), a pioneer in affordable medicines, and the COPD Foundation, dedicated to enhancing the lives of COPD patients. This collaboration aims to bolster access to healthcare by expanding the availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, to COPD patients in the US.

September 6, 2023

EOSERA announces the opening of a new facility featuring an expanded office space and manufacturing footprint. The growth highlights the leadership position EOSERA took in the ear care market. With a dedicated workforce of 30 employees and best-in-class products such as Earwax MD and Ear Pain MD now available in over 28,000 retail stores, EOSERA disrupts the sleepy ear care category with new technology and innovative go-to-market strategy.

September 6, 2023

OncoNano Medicine, Inc. announced a clinical trial supply agreement with Regeneron for the use of Libtayo® (cemiplimab), a PD-1 inhibitor, in the combination stage of the first human trial of ONM-501, a dual-activating STING (STimulator of INterferon Genes) agonist and lead therapeutic development candidate.

August 29, 2023

Golgi Neurosciences S.r.l., a new Italian incubator dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases, announced that it has adopted Collaborative Drug Discovery’s CDD Vault as its platform of choice for managing drug discovery data. This integration will streamline the Company’s processes and collaborations, allowing for more efficient research and development.

August 29, 2023

RS BioTherapeutics, a life sciences company developing life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, has entered into a Research Collaboration Agreement with the National Institute on Alcohol Abuse and Alcoholism (NIAAA), an institute within the National Institutes of Health (NIH), to assess the anti-inflammatory and anti-fibrotic potential of RS BioTherapeutics’ lead compound, RSBT-001, in a preclinical pulmonary fibrosis model.

August 29, 2023

Spark Biomedical, Inc., a Dallas-based pioneer in wearable neurostimulation technology, was awarded a $1.15M Phase II grant to develop a Transcutaneous Auricular Neurostimulation (tAN®) device, Sparrow® Hawk, to address the adverse effects of acute stress reaction (ASR). In partnership with Battelle, Sparrow Hawk development brings a rapidly deployable, non-invasive, wearable approach to ASR prevention and treatment into the battlefield setting.

August 28, 2023

Lantern Pharma Inc., an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, announced a substantial increase in the power and capabilities of RADR® focused on improving the drug development process for immune checkpoint inhibitors (ICIs).

August 24, 2023

Fresenius Kabi and Lupagen Inc. announced that the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside.

Under the terms of the agreement, Fresenius Kabi will provide their expertise in apheresis collection and automated cell processing equipment to advance Lupagen’s Extracorporeal Cell and Gene Therapy Delivery System, which focuses on simplifying and reducing costs for cell and gene therapy through a bedside procedure.

August 24, 2023

Taysha Gene Therapies, Inc., a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), announced the U.S. FDA has granted Fast Track Designation (FTD) to TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome. TSHA-102 utilizes the novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression.

August 24, 2023

Lifecycle Biotechnologies L.P. and WORK-FLOW are thrilled to announce a licensing agreement to commercialize and develop a new line of reagents for flow cytometry markets. Cody Yarborough, Lifecycle CEO, stated “This collaboration exemplifies Lifecycle’s commitment to innovate quality products and being pertinent to needs of the market. Collaborating closely with WORK-FLOW, known for their deep technical knowledge of flow cytometry applications and their forward-thinking approach to market demands, promises to significantly elevate our sheath fluid product portfolio. This really is a great marriage of product innovation and manufacturing expertise that will benefit both of our expanding customer bases.”

August 21, 2023

GordonMD® Global Investments LP announced it has participated in a $150 million private placement financing for Taysha Gene Therapies, Inc., a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS).

“Over the last 13 years, gene therapies have been or are being developed for a wide range of rare diseases, said Craig Gordon, M.D., founder, chief executive officer, and chief investment officer of Gordon MD® Global Investments. I am excited to help fund the development of such a therapy for the potential treatment of Rett Syndrome.

August 21, 2023

In the largest initiative of American mammoth research ever conducted, Colossal Biosciences, the breakthrough genetic engineering and de-extinction company, in partnership with the University of Alaska Fairbanks, has announced that the first-of-its-kind “Mammoth in the Classroom” initiative has reached its initial research and adoption goal. Through this important initiative, which is part of the Adopt a Mammoth program, 55 mammoth fossils have been donated to school districts across the state of Alaska, allowing students to participate in this scientific discovery.

“Colossal's ‘Mammoth in the Classroom’ initiative has helped us get closer to reaching our goal of classifying the mammoth fossils in our vast collection while also getting kids interested in science and ecology from an early age,” said Dr. Wooller. “Not only has this been a great opportunity for school kids in Alaska, but the research will help contribute to woolly mammoth education worldwide and an opportunity to identify some of the last surviving mammoths on the mainland, which has never been done before.”

August 14, 2023

Lantern Pharma Inc., an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (ML) platform with multiple clinical-stage drug programs, received a notice of allowance from the United States Patent and Trademark Office (USPTO) covering a method of treatment for Atypical Teratoid Rhabdoid Tumor using LP-184, an aggressive and rapidly growing form of cancer of the central nervous system.

August 10, 2023

Alpha Cognition Inc., a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announced the United States Patent and Trademark Office has issued a Notice of Allowance for patent application No. 17/575,025, titled “Solid Forms of ALPHA-1062 Gluconate,” which includes claims covering protection for crystalline solid forms of ALPHA-1062 and will bolster existing patents that the company holds. A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application.

August 10, 2023

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce a Request for Information (RFI) related to a planned method development study, focused on the development and optimization of Next-Generation Sequencing (NGS) methods for extended characterization of Adeno-Associated Virus (AAV) gene therapy vectors.

The planned study aims to promote collaboration among multiple laboratories and industry partners to enhance the reliability, consistency, and understanding of AAV vector properties using NGS-based analysis methods.

August 9, 2023

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company focused on gene therapies for retinal degenerative diseases, presented key results from its Phase 2 clinical trial, STARLIGHT, at the American Society of Retina Specialists (ASRS) annual meeting in Seattle. The trial evaluated the effects of their novel therapeutic, MCO-010, for patients with Stargardt disease, a condition currently lacking available treatments.

August 8, 2023

Spark Biomedical Inc., a U.S. leader in wearable neurostimulation solutions, is proud to announce the launch of telehealth services for their recently FDA-cleared product, Sparrow Ascent. Through partnership with existing telehealth networks, Sparrow Ascent can now be prescribed and e-prescriptions administered all via remote patient access. Sparrow Ascent— a safe, drug-free opioid withdrawal treatment — provides a much-needed treatment option to patients seeking to decrease or eliminate their reliance on opioids and who can or won't access facility-directed care. Pairing Sparrow Ascent and the telehealth home-based treatment option, the journey to recovery can now be more comfortable, more flexible, and more accessible, empowering patients to take the first critical step toward recovery.

August 3, 2023

Scripta Insights, the Rx Navigation™ company that guides self-insured employers, health plans and their members to prescription savings, announced today a collaboration with Mark Cuban Cost Plus Drug Company, PBC. The companies are committed to working together to make prescription drugs more accessible and affordable to patients. The relationship furthers Scripta's mission to get members The Right Meds at The Best Price™.

"Cost Plus Drugs and Scripta Insights share a common goal of providing consumers the lowest possible price for their prescription medications. With Cost Plus Drugs, consumers can be confident they are getting a fair price and the convenience of medication mailed directly to their homes," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.

August 3, 2023

CAGE Bio, Inc., a biotechnology company focused on developing innovative drug therapies for localized treatment of immuno-dermatological disorders, announced positive results from its randomized, vehicle controlled, phase 2 study evaluating the safety and efficacy of CGB-500, an ionic liquid formulation of 1% Tofacitinib, in patients with Atopic Dermatitis (AD).

July 28, 2023

Biogen Inc. and Reata Pharmaceuticals, Inc. announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.

“Biogen’s expertise and commercial footprint make it the optimal choice to help SKYCLARYS realize its full potential,” said Warren Huff, Chairman and Chief Executive Officer of Reata. “With its clear understanding of the rare disease patient journey and existing commercial infrastructure, we believe Biogen will establish SKYCLARYS as the standard of care in the treatment of this devastating genetic disease.”

July 27, 2023

Fina Biosolutions has selected Scorpius BioManufacturing, a biologics contract development and manufacturing organization (CDMO), for the production of an E.coli-expressed CRM197 conjugate vaccine carrier protein.

The partnership includes recovery and downstream process optimization, analytical method implementation and phase-appropriate validation, scale-up, and cGMP bulk drug substance manufacturing of CRM197, a genetically detoxified diphtheria toxin widely used in conjugate vaccines. FinaBio markets their CRM197 under the tradename EcoCRM®.

July 27, 2023

Opsin Biotherapeutics, Inc., a joint venture between DesignPlex Biomedical and Nanoscope Technologies, has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant from the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH).

It will be utilized to advance the study and development of a non-viral, gene delivery system for optogenetic neuromodulation of the spine, providing a groundbreaking solution for severe chronic pain management without the need for opioids.

July 27, 2023

Life sciences manufacturer Lifecycle Biotechnologies has officially entered into a preferred partnership with Savillex, a Minnesota-headquartered provider of polymer-based solutions designed for life sciences and laboratory applications.

“We are excited to announce our partnership with Savillex. United by our commitment to excellence, integrity, and customer-centricity, this amplifies customers’ access to discover how the HELIX can enhance their productivity and drive impactful discoveries,” said Cody Yarborough, CEO of Lifecycle Biotechnologies.

July 26, 2023

AbbVie and Calibr announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas including immunology, oncology, neuroscience and other areas of interest.

"We've made significant progress to advance rapidly many preclinical and clinical development programs across small molecule, biologics and CAR-T modalities," said Thomas Hudson, M.D., senior vice president, research and development, chief scientific officer, AbbVie. "Working together with Calibr, AbbVie is excited to explore and further develop the potential of novel technologies and new clinical indications to bring breakthrough medicines to patients."

July 25, 2023

Am Law 100 firm Polsinelli’s Intellectual Property Department has been recognized among the prestigious IAM Patent 1000 – The World’s Leading Patent Professionals 2023 for its strong patent prosecution and patent litigation capabilities.

This is the fourth time Polsinelli has ranked at the national level on the IAM Patent 1000 list. Polsinelli’s Intellectual Property Department again earned rankings in Colorado and Texas for the Litigation and Prosecution categories, and also received Prosecution category rankings in Washington state and in D.C. (newly ranked). The firm also repeated its national ranking in the Prosecution category. Eighteen Polsinelli attorneys received individual rankings.

July 21, 2023

Patients who use Mark Cuban’s Cost Plus Drugs can now pick up some of their prescriptions at one of the 2,000 stores operated by Kroger

Mark Cuban, the billionaire known for owning the Dallas Mavericks NBA team as well as his appearances on “Shark Tank,” started Cost Plus in 2022. The company is “dedicated to producing low-cost versions of high-cost generic drugs,” according to its website, with a goal of transparency when it comes to manufacturing, distribution, and marketing of its drugs to pharmacies.

July 19, 2023

Colossal Biosciences, the world’s first de-extinction company, has announced an integrated partnership with Elephant Havens Wildlife Foundation, the only elephant orphanage in Botswana, to establish a new model playbook for reintroducing orphan elephants back into the wild. Colossal will deploy artificial intelligence (AI) technology to enable comparative analysis between the behaviors of orphaned elephants and those observed in wild elephants.

July 11, 2023

Renibus Therapeutics, Inc., a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to RBT-1 for the reduction in risk of post-operative complications in patients undergoing cardiothoracic surgery, and confirmed its alignment with the Company’s planned Phase 3 pivotal trial.

July 11, 2023

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces U.S. Food and Drug Administration (FDA) clearance of the company’s investigational new drug (IND) application to commence a Phase 1 clinical trial with SP-3164 in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Salarius expects to begin treating patients in the dose-escalation portion of the trial in the second half of 2023 to evaluate safety, clinical activity, pharmacokinetics and pharmacodynamics.

“FDA clearance of the SP-3164 IND marks another significant milestone for Salarius and demonstrates our continued focus and commitment to bringing new therapies to patients in need of new treatment options,” said David Arthur, president and chief executive officer of Salarius, ”We now plan to enroll NHL patients in the dose-escalation portion of the clinical trial and will then focus on patients with diffuse large B-cell lymphoma (DLBCL) in the second portion of the trial.”

July 11, 2023

Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking product, Sparrow Ascent, has received clearance from the U.S. Food and Drug Administration (FDA). Sparrow Ascent is a wearable neurostimulation device designed to provide safe, comfortable, drug-free relief for individuals experiencing opioid withdrawal symptoms.

July 6, 2023

Five Liters, a subsidiary of Spark Biomedical and Dallas-based wearable neuromodulation company, is embarking on a series of groundbreaking first-in-human studies to demonstrate the effectiveness of non-invasive, wearable neurostimulation in reducing blood loss. This significant milestone is made possible through Five Liters' collaboration with the Feinstein Institutes for Medical Research, marking the first translational step from their recently published Nature Communications study titled Vagus nerve stimulation primes platelets and reduces bleeding in hemophilia A male mice.

June 29, 2023

FUJIFILM Corporation announced that the company has appointed Lars Petersen as the new president and chief executive officer (CEO) of FUJIFILM Diosynth Biotechnologies, effective immediately. Petersen succeeds Martin Meeson who has served as FUJIFILM Diosynth Biotechnologies president and CEO since 2020.

“His organizational knowledge, breadth and depth of experience in biopharmaceuticals make him the ideal leader to spearhead the company successfully through its next growth phase,” said Toshi Iida, corporate vice president of FUJIFILM Corporation

June 29, 2023

Mark Cuban Cost Plus Drug Company (MCCPDC) has announced a partnership with male fertility and sexual healthcare company Posterity Health to provide males access to medications to treat infertility, sexual dysfunction and low testosterone.

Posterity Health is a digital male fertility clinic providing access to reproductive urologists who diagnose and treat sexual health and male fertility issues. The company offers sperm cryopreservation, in-clinic or in-home fertility testing, vasectomy and vasectomy reversal.

June 29, 2023

Scorpius BioManufacturing, a biologics contract development and manufacturing organization (CDMO), expanded its leadership team to include Matthew R. LeClair as VP, Manufacturing Operations.

“This is a once-in-a-career opportunity to build a premier biomanufacturing company from the ground up, and to build it the right way," said LeClair, who is also a United States Navy veteran. "Scorpius has made incredible progress so far, and I'm honored to help the company become leaders in both clinical and commercial biomanufacturing. Our team has an exciting second half of the year ahead of us with aggressive hiring plans and helping our current clients advance their clinical programs."

June 28, 2023

Reata Pharmaceuticals (RETA) won the Food and Drug Administration's blessing to go ahead with production of its Friedreich's ataxia drug. RETA stock advanced in response. Reata's Skyclarys is the first treatment approved for Friedreich's ataxia. It's a once-daily pill. The company also is working to win approval in Europe.

June 26, 2023

S&W Seed Company, a global agricultural company, announced the appointment of seed industry veteran Mark Herrmann as Chief Executive Officer, effective July 1, 2023, following the planned retirement of current CEO, Mark Wong. Wong will continue to serve as a member of S&W’s Board of Directors.

Mark Herrmann said, “I am honored to have the opportunity to lead S&W as we embark on an exciting future for the company. I look forward to leveraging my career experiences in the seed business to bring continued positive impact to our customers, employees and shareholders.”

June 26, 2023

Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment of underserved diseases, announced the appointment of Deepa Prasad as Chief Financial Officer.

"I am truly excited to be joining Secretome at this pivotal time in the company’s history. I believe that secretomes represent a true breakthrough in the field of cell-based therapy, and I look forward to helping Secretome transform the way we treat diseases," said Ms. Prasad.

June 22, 2023

McKesson, a diversified healthcare services company, announced the launch of Foster & Thrive™, a curated private brand of over-the-counter (OTC) health and wellness products. Launching Foster & Thrive unifies the company’s private brand portfolio—consolidating Health Mart® and Sunmark® branded OTC products—to offer expanded availability through increased production volumes and efficiencies that will help meet evolving patient needs and growing demand.

June 21, 2023

Mark Cuban Cost Plus has been named one of TIME 's 100 most influential companies.

TIME recognized 100 companies from around the world across a variety of sectors, including health care, entertainment, technology, transportation, retail, energy and more.

June 20, 2023

Johnson & Johnson announced the launch of Illustrate Change, a new initiative that aims to increase diversity and representation in medical illustrations. The initiative includes a growing library of diverse medical illustrations, a fellowship to support the future of medical illustrators of color, and an awareness campaign to help bring lasting change in the U.S. healthcare system and vision for a more inclusive future for patients of color.

June 18, 2023

DKSH has entered a partnership with Wuxi Nest Biotechnology, a leading provider of plastic laboratory products suitable for life science research. DKSH will provide sales, marketing, and after-sales services in Australia, Indonesia, New Zealand, the Philippines, Singapore, Thailand, and Vietnam.

“DKSH offers great market coverage in Southeast Asia and has a strong focus in the life sciences segment. We believe that DKSH is the right partner to help us expand the business, penetrate the cell culture market, and meet our growth goals,” said Frank Liu, Oversea Sales Manager, Wuxi Nest Biotechnology.

June 14, 2023

Alcanza Clinical Research, mission-driven investigator site network, announced a strategic partnership with Reveles, a provider of equity-driven decentralized clinical trials.

The collaboration is designed to foster health equity through a focus on next-generation hybrid decentralized models. A range of decentralized tools and services, including in-home clinical trial support services, direct-to-patient shipping and technology that enable home-based participation will help lower the burden of clinical trial participation in traditionally underrepresented and marginalized communities.

June 14, 2023

Colossal Biosciences was named one of the best and brightest companies that are commercializing scientific research into deep technology and impacting society in a profound way.

The XB100 is the definitive ranking of the world’s top 100 private deep technology companies, brought to you by XPRIZE and Bessemer Venture Partners.

June 12, 2023

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple clinical stage drug programs, announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumors and central nervous system cancers. The first-in-human Phase 1A trial for LP-184 is anticipated to launch and dose its first patient during the current quarter.

June 8, 2023

Lantern Pharma Inc., a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced it will be leveraging its AI platform, RADR®, in a research collaboration with Bielefeld University (Bielefeld, Germany) to develop antibody-drug conjugates (ADCs) with high therapeutic and antitumor potential. The collaboration will leverage insights from Lantern’s recently developed RADR® AI ADC module in combination with research from Professor Norbert Sewald, Ph.D., the principal investigator for Bielefeld and leader of Magicbullet::reloaded, a European consortium focused on developing novel drug delivery mechanisms, including ADCs.

June 5, 2023

JLL announced that it placed at number 190 on the prestigious Fortune 500 list, which ranks the 500 largest companies based in the United States by total revenue for their respective fiscal years.

"Around the world, JLL is committed to providing clients with outstanding real estate advice and solutions, combining industry leading talent, technology and data-driven insights," said Christian Ulbrich, JLL CEO. "Our continued recognition as one of the top 200 companies in the Fortune 500 list reflects our resiliency and strong performance even during times of geopolitical challenge and economic volatility."

June 1, 2023

Caris Life Sciences®, the leading molecular science, artificial intelligence (AI) and machine learning technology company actively developing and delivering innovative solutions to revolutionize healthcare, and ConcertAI, the leading oncology real-world evidence data and AI technology company, announced an expanded translational sciences and clinical development solutions partnership.

June 1, 2023

Mark Cuban Cost Plus Drug Company, PBC and Coherus BioSciences, Inc., announced plans to offer Mark Cuban Cost Plus Drug Company customers YUSIMRY (adalimumab-aqvh), a biosimilar of HUMIRA® (adalimumab injection), in July 2023.

“Humira is the top-selling medicine of all time, but for those without insurance or who are underinsured, this therapy and other biologic medicines have been out of reach due to price,” said Alex Oshmyansky, Co-Founder and CEO, Mark Cuban Cost Plus Drug Company.

May 31, 2023

OncoNano Medicine, Inc. will present positive final results from its Phase 2 study of pegsitacianine, a pH-sensitive fluorescent nanoprobe for enhanced intra-operative visualization of cancer, in a podium presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023. Results of the study show that acidic pH is a viable marker and can be used for tumor targeting by the company’s ON-BOARD™ micelle platform.

May 30, 2023

High-level findings from the Phase III DUO-E study showed AstraZeneca’s Imfinzi (durvalumab), either alone or in combination with its Lynparza (olaparib), improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer.

“These exciting data demonstrate durvalumab immunotherapy can significantly delay disease progression for patients with endometrial cancer and the addition of the PARP inhibitor olaparib can improve the benefit further,” Shannon Westin, principal investigator of DUO-E, said in a statement, adding that this treatment combo could result in new treatment approaches and leading to better outcomes.

May 19, 2023

Taysha Gene Therapies, Inc., a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), presents preclinical data from neonatal mouse models on TSHA-102 for Rett syndrome, including new data in wild-type mice, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.

May 18, 2023

Colossal Biosciences, the Dallas company working to bring back the woolly mammoth and Tasmanian tiger, is one step closer to its ambitious goals after generating the first high-quality reference genome of an African elephant.

The de-extinction company is working in partnership with the Vertebrate Genomes Project to ensure the survival of elephant species. The work illustrates a step forward in animal conservation and the future advances of Colossal’s efforts. Last year, the partnership announced a near complete sequence of the Asian elephant genome.

May 17, 2023

AyuVis has been awarded a $2.1 million National Institute of Health research grant from the National Heart, Lung, and Blood Institute that will fund preparations and the initiation of a first-in-human Phase 1 clinical trial.

AyuVis is developing a new generation of immunotherapies, including AVR-48, that, rather than simply activating or suppressing the immune response, provides a well-balanced outcome where mild activation and controlled suppression of the immune system is needed to effectively treat disease. This process allows the drug to control inflammation and infection.

May 16, 2023

Pulvinar Neuro, a wholly owned subsidiary of Electromedical Products International, Inc. (EPI) developing non-invasive brain stimulation devices, was awarded a grant from the National Institutes of Health (NIH) to further its research in transcranial stimulation (TCS) as a potential treatment for psychiatric disorders.

The three-year, $3.06 million Phase II SBIR grant from the NIH’s National Institute of Mental Health (NIMH) will be used to develop a cloud-enabled TCS device that delivers personalized closed-loop brain stimulation for clinical and at-home applications. The grant also includes funding for a double-blind, placebo-controlled study of the cloud-enabled TCS device in 30 patients with major depressive disorder.

May 15, 2023

RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life changing medicines, is pleased to announce that is has joined BioNTX, the bioscience and healthcare innovation trade organization serving North Texas. BioNTX is also an affiliate of the Biotechnology Innovation Organization in Washington, D.C.

As a member of BioNTX, RS BioTherapeutics will benefit from BioNTX’s various resources and benefits including legislative advocacy; networking, education and business collaboration opportunities; business services discounts through a purchasing consortium; and access to the organization’s talent network for recruiting.

May 11, 2023

Form Bio, the provider of advanced computational life sciences technology announced the launch of FORMsightAI – a new, AI-based solution set for predicting and optimizing manufacturing outputs of cell and gene therapy constructs. Form Bio FORMsightAI is generally available to cell and gene therapy companies as well as CDMOs.

Form Bio FORMsightAI is a full service solution that incorporates advanced, customizable AI models, Form Bio’s underlying platform and the company’s experienced team of computational life sciences professionals with expertise spanning biology, bioinformatics and data science.

May 11, 2023

S&W Seed Company, a global agricultural company, announced that its Board of Directors is evaluating potential avenues to unlock what the Company sees as unrecognized value in its international operations, which are headquartered within the Company's Australian subsidiary.

Mark Wong, CEO, commented: "Australia is a large and important agricultural market and plays an integral role in the global food supply chain. It also has a vibrant public and private equity agricultural investment community, as well as several mid-sized agricultural companies. We believe now is the right time for us to conduct an accelerated review of our international operations, with a view towards evaluating potential strategic opportunities that could unlock unrecognized value for the benefit of all our stakeholders."

May 10, 2023

Reata Pharmaceuticals, Inc., a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced financial results for the first quarter of 2023 and provided an update on the Company’s business operations and clinical development programs.

In the first quarter of 2023, Reata announced FDA approval of SKYCLARYS (omaveloxolone) for the treatment of FA in adults and adolescents aged 16 years and older. In early March 2023, they deployed their fully trained and experienced field sales team as well as the infrastructure that enables physicians to initiate start forms for FA patients. They have received approximately 500 patient start forms to date.

May 9, 2023

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces that the U.S. Food and Drug Administration (FDA) has removed its partial clinical hold on Salarius’ Phase 1/2 Ewing sarcoma clinical trial evaluating seclidemstat, Salarius’ novel oral, reversible, targeted LSD1 inhibitor.

“The FDA’s decision to remove the clinical hold puts us back on track to engage in dialogue with the FDA on various topics relating to further clinical development of seclidemstat and possible registration pathways. As we gain clarity in those discussions, we intend to provide updates to our investors,” CEO, David Arthur added.

May 9, 2023

Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that Yale Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.

May 4, 2023

eNavvi, Inc., a leading provider prescription marketplace, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), an innovator in offering transparently priced medications, are thrilled to announce their new collaboration focused on delivering prescription cost transparency.

As an innovator in the cash price market, Cost Plus Drugs has expanded to cover a broad array of medications at prices often less than what most insurance plans' deductible and copay requirements would total. This collaboration with Cost Plus Drugs will empower eNavvi's Marketplace to provide real-time cash-price transparency directly to physicians, ultimately making medications more affordable and accessible for patients.

May 2, 2023

Lantern Pharma Inc., a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that it has developed highly-accurate and industry-leading AI algorithms to predict the ability of a drug or compound to pass the blood-brain-barrier (BBB), a highly selective border that can prevent drugs from entering brain tissues.

May 1, 2023

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the completion of two Good Laboratory Practice (GLP) toxicology studies with its targeted protein degrader SP-3164, with no unexpected safety findings during the course of either study. These GLP toxicology reports will be included in the Investigational New Drug (IND) application the company plans to submit to the U.S. Food and Drug Administration (FDA) in the second quarter of 2023.

April 27, 2023

OncoNano Medicine, Inc. announced an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, taking place June 2-6, 2023 at McCormick Place, Chicago, Illinois. They will go over the final results from their Phase 2 study of pegsitacianine for image-guided cancer surgery featured in an oral presentation.

April 26, 2023

Galderma announced that the U.S. Food and Drug Administration (FDA) has approved Sculptra® (injectable poly-L-lactic acid (PLLA-SCA)) for the correction of fine lines and wrinkles in the cheek area.

Sculptra is the first and original FDA-approved PLLA collagen stimulator that, when injected into the cheek area, helps stimulate natural collagen production to smooth wrinkles and improve skin quality such as firmness and glow, with results lasting up to 2 years.

April 21, 2023

GL CHEMTEC, a specialist in advanced chemistry R&D and scale-up services to support Active Pharmaceutical Ingredient development, and the development of advanced materials for drug delivery, medical devices, and other life science applications, announced the formation of its Scientific Advisory Board comprised of distinguished leaders in Small Molecule R&D (Chemistry/Biology), Process Development & Scale-Up, Green Chemistry, Medical Devices and Drug Delivery.

Lisa Studnicki Hunt, Ph.D., COO and Co-Founder of GLC commented, “We are proud and honoured to introduce GL CHEMTEC’s inaugural SAB. This is a team of world leaders in their respective fields who bring a wealth of experience to our company during our next phase of growth. We can’t thank these outstanding individuals enough for committing their time and expertise to GL CHEMTEC’s success.”

April 19, 2023

Form Bio, the provider of advanced computational life sciences technology, today announced it has joined the PacBio Compatible program. As part of the program, the Form Bio platform has been verified as compatible with PacBio's HiFi sequencing solutions, empowering corporate and academic research teams with a dramatically streamlined path from HiFi read data to breakthrough insights.

In particular, AAV-based gene therapy can address the underlying genetic problems that cause disease and holds great promise to help improve human health. With the combination of Form Bio's data analysis capabilities and PacBio's sequencing solutions, scientists can enhance their understanding of the genetic components underlying disease and ultimately improve AAV gene therapies in their application to a vast spectrum of diseases.

April 18, 2023

OncoNano Medicine, Inc. presented three posters at the American Association for Cancer Research (AACR) Annual Meeting 2023. The posters detail positive nonclinical data for ONM-501, the Company’s dual-activating STING (STimulator of INterferon Genes) agonist and lead therapeutic development candidate, formulated with the company’s OMNI™ polymer technology as well as positive data for encapsulated bispecific antibody and cytokine using ON-BOARD™ tumor specific delivery technology.

April 17, 2023

Island Pharmaceuticals Ltd has formally filed its response to the FDA after a review of all aspects of the company’s original Investigational New Drug (IND) submission for ISLA-101.

The antiviral drug development company’s lead asset ISLA-101 is being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a 'Priority Review Voucher' at the time of FDA approval, which would not only give it approval to manufacture and sell ISLA-101 but could also allow Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

April 13, 2023

Caris Life Sciences, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, announced a multi-year strategic collaboration to accelerate precision medicine approaches across five of Flare’s therapeutic programs into clinical trials through advanced molecular profiling approaches that guide patient selection and participation.

April 13, 2023

Lantern Pharma Inc., a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. patent application no. 17/192,838 directed to Lantern Pharma’s drug candidate LP-284 ((+)N-hydroxy-N-(methylacylfulvene)urea). The allowed application entitled “Illudin Analogs, Uses Thereof, and Methods for Synthesizing the same” covers the molecule LP-284, including claims covering the new molecular entity itself.

April 12, 2023

Nuvothera, a Fort Worth, Texas-based biotech company, has reached agreement to have its revolutionary Prosoria Psoriasis Treatment System available nationwide in Walgreens.

Prosoria is an effective, over-the-counter treatment with long-lasting results for a tough-to-treat skin condition. Formulated with maximum-strength ingredients, botanicals and vitamins, Prosoria effectively relieves psoriasis symptoms and is safe for daily use. The formula is steroid- free, paraben-free, and fragrance-free.

"Getting into retail drugstores is a game changer for Nuvothera. This significant milestone enables us to quickly launch products and reach significantly more people with skin conditions. The drugstore channel is huge, and we have prepared for rapid growth."

April 10, 2023

Am Law 100 firm Polsinelli is pleased to announce that it has once again been ranked by Patexia as one of the “most active” and “best performing” law firms in the country for patent litigation and patent prosecution.

Polsinelli received multiple Top 50 and higher most active and best performing rankings in both the 2023 Patent Litigation Intelligence Report and the 2023 Patent Prosecution Intelligence Report, including a #12 ranking for best performing patent prosecution firms in the high-tech sector and #26 in biotech. The firm has been included in these prestigious reports since their inception. Each report analyzes and evaluates more than 3,000 firms and their respective patent prosecution and litigation matters by activity and performance.

April 5, 2023

Zócalo Health, the healthcare company reinventing primary care delivery and care navigation for the Latino patient, announced its collaboration with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to focus on improving access to all medications available through Cost Plus Drugs. Zócalo Health, launched in 2021, is focused on removing barriers to quality primary care for Latino patients. All users of Zócalo Health will have access to Cost Plus Drugs' prescriptions through membership packages or one-time urgent care visits.

April 1, 2023

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) issues Part II of a whitepaper series titled Innovation of the Biopharmaceutical Manufacturing Talent Pipeline, a series focused on highlighting non-traditional and novel solutions for the talent pipeline gap in the biopharmaceutical industry. The newest whitepaper focuses on successes and challenges faced by community college biotechnology degree programs and makes the case for stronger engagement between industry and community colleges.

April 1, 2023

TDIndustries, a premier facilities service and mechanical construction firm, announced that it received a National Inclusion, Diversity and Equity Excellence Award from Associated Builders and Contractors (ABC).

“At TDIndustries, we celebrate the power of individual differences and value the unique perspectives of our employee-owners,” said Chief People Officer Steve Cunningham.

The National Inclusion, Diversity and Equity Excellence (IDE) Awards recognize ABC members that display exemplary IDE leadership in their company, workforce, supply chain and community with best-in-class recruitment policies, retention practices and training and mentoring programs. TDIndustries won in the Subcontractor category.

March 31, 2023

Scorpius BioManufacturing, a Texas-based biologics contract research and contract development & manufacturing organization (CDMO), announced the appointment of Gary Welch as Interim President. With a career spanning more than 30 years in biopharmaceuticals at large manufacturers like AbbVie and biotech innovators like Agensys and CytomX, Gary will lead Scorpius through its next phase of growth, focused on serving clients working on mammalian & microbial biologics and new modalities.

Jeff Wolf, Executive Chairman of Scorpius, said, “With extensive experience in process engineering, manufacturing, analytical development, CMC, and site operations, Gary brings a wealth of knowledge to the team. His leadership will help Scorpius to continue on our path to becoming a world-class CDMO.”

March 30, 2023

Nanoscope Therapeutics Inc., announced topline results from the Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation. MCO-010 has received both orphan drug and fast track designations from the U.S. Food and Drug Administration (FDA).

March 28, 2023

Society for Science is proud to announce that the organization has distributed $263,700 to regional, state and national science fairs in 2023 through the Equitable Access Fund for Affiliated Science Fairs. Grants provided by the fund support fairs as they expand their reach to ensure inclusivity and support historically underserved populations. These funds are helping fairs continue to build capacity and invest in foundational improvements so that they can continue to offer the best opportunities to the students they serve.

March 28, 2023

Lantern Pharma Inc., a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced the dosing of the first patient in the Phase 2 Harmonic™ clinical trial evaluating Lantern’s investigational new drug LP-300 in combination with chemotherapy for never smokers with advanced non-small cell lung cancer.

March 27, 2023

OncoNano Medicine, Inc. presented data from a Phase 2 study of pegsitacianine, a pH-sensitive fluorescent nanoprobe for image-guided cancer surgery, at the Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care, occurring March 22-25 in Boston, MA. Data from the study revealed that the primary endpoint was achieved in 50% of the evaluable patients undergoing peritoneal carcinomatosis surgery.

March 27, 2023

Dallas-based MedCognetics is using AI to take cancer detection to the next level. The company’s medical imaging tech works to pinpoint early signs of breast cancer based on an extensively trained machine learning model. Its system is designed to assist radiologists as they conduct mammograms and review the scans’ findings.

As MedCognetics continues to pursue its work of reducing bias in medical imaging, the healthtech company plans to expand its cancer detection capabilities into additional parts of the body, like lung cancer for instance, Ron Nag, CEO and co-founder of MedCognetics said.

March 20, 2023

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that the company received the “Best Contract Development and Manufacturing Organization Award” and the “Bioprocessing Excellence in Greater China Region Award” at the 2023 APAC Bioprocessing Excellence Awards (ABEA) ceremony. This marks the sixth time that the company has received an award from the organizer IMAPAC, a professional consulting firm in the biopharmaceutical industry.

March 20, 2023

Am Law 100 firm Polsinelli has been recognized in PitchBook’s 2022 Global League Tables as being amongst the most active law firms for advising on mergers & acquisitions, private equity and venture capital deals.

Throughout 2022 alone, the firm’s Mergers & Acquisitions Practice closed 333 with a total value of $17 billion. Polsinelli's Private Equity Practice closed a total of 154 M&A transactions with more than $8.4 billion in total transaction value across 13 different industries.

March 16, 2023

Avantor, a leading global provider of mission-critical products and services to customers in the life sciences, education, government and advanced technologies & applied materials industries, has been accorded the Best Bioprocessing Company for Chromatography at the Asia-Pacific Bioprocessing Excellence Awards 2023 (ABEA).

The award recognizes Avantor's ongoing efforts to provide innovative chromatography solutions that enable biopharmaceutical manufacturers to optimize processes and enhance product quality. With over four decades of experience in bioprocessing, Avantor is committed to addressing the complex challenges of downstream chromatography by providing a comprehensive range of equipment, products and services.

March 15, 2023

ReCode Therapeutics, a private, clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced that the first healthy volunteer participants have been dosed in a Phase 1 clinical trial of RCT1100, a first-in-class, mRNA-based genetic medicine for the treatment of people with primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene.

March 15, 2023

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announced that two abstracts related to the company’s novel molecular glue SP-3164 have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19 at the Orange County Convention Center in Orlando, Florida and also virtually. Both abstracts highlight preclinical activity with SP-3164, one focused on non-Hodgkin’s lymphoma (NHL) and the other on multiple myeloma (MM).

March 14, 2023

OncoNano Medicine, Inc. announced three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023 at the Orange County Convention Center, Orlando, Florida.

March 9, 2023

Lantern Pharma Inc., a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced new data for its product candidate LP-100 supporting the development of LP-100 in combination with the class of anticancer agents known as PARP inhibitors.

Lantern believes the simultaneous exploitation of both these mechanisms will enhance the development opportunities for LP-100, while also expanding potential market opportunities for existing PARP inhibitors.

March 7, 2023

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced a strategic research partnership with Incyte Corporation to augment precision medicine approaches for Incyte’s oncology pipeline.

March 6, 2023

Lantern Pharma Inc., a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that it has formed a wholly-owned subsidiary, Starlight Therapeutics Inc., to develop drug candidate LP-184’s central nervous system and brain cancer indications – including glioblastoma , brain metastases, and several rare pediatric CNS cancers.

March 3, 2023

Cooley’s life sciences practice has been named one of Law360’s Practice Groups of the Year based in part on representation of Arena Pharmaceuticals in its sale to Pfizer and Turning Point Therapeutics in its sale to Bristol Myers Squibb.

Law360’s Practice Group of the Year awards honor the law firms behind the major deals and litigation wins that resonated throughout the legal industry in the past year. Winning firms rose to the top of nearly 900 submissions.

February 28, 2023

Seizing on an opportunity to solve a major industry pain point, Scott Nudelman and Sam Johnson formally launched Vitrian in the summer of 2022. Headquartered in Bethesda, Maryland with additional offices in New York and Dallas, Vitrian deploys a differentiated business model that offers a full lifecycle, end-to-end solution for cGMP and biomanufacturing projects.

Today, Vitrian is set-up as a first-of-its-kind company to help life sciences companies accelerate the creation of biomanufacturing capacity, through a single, fully-managed platform. Instead of companies having to retain separate consultants and investors, Vitrian offers everything in-house between facility procurement and development, investment capital and assistance with site selection and workforce development.

February 28, 2023

Reata Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that the U.S. Food and Drug Administration has approved SKYCLARYS™ for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older. With this approval, the FDA granted a rare pediatric disease priority review voucher.

"The approval of SKYCLARYS, the first therapy specifically indicated for the treatment of Friedreich’s ataxia, is an important milestone for patients affected by this disease as well as their families and caregivers," said Warren Huff, Reata's Chief Executive Officer.

February 27, 2023

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that it has entered into a research and development collaboration with TTC Oncology. The collaboration will focus on leveraging RADR® AI insights to advance TTC Oncology’s first- and best-in-class drug candidate TTC-352 for recurrent ER+ breast cancer patients and additional patient populations potentially identified by RADR®.

February 21, 2023

Cooley has again been named the #1 law firm representing companies in venture capital financings in the US and globally for the third consecutive year as part of PitchBook’s 2022 Annual Global League Tables, a comprehensive, year-end report on the top investors, advisers and more across private equity and venture capital.

PitchBook also designated Cooley as the second-most active law firm overall in the US and globally, as well as the second-most active law firm representing investors in venture capital deals.

February 20, 2023

Diathrive Health, a diabetes and chronic disease management solution, and Mark Cuban Cost Plus Drug Company, PBC have announced a new collaboration, focused on improving healthcare access, lowering costs, and improving outcomes for people living with diabetes and other chronic diseases.

Cost Plus Drugs and Diathrive Health are both industry disruptors. The relationship will give consumers lower cost medications and diabetes testing supplies and more personalized, higher quality care so that they can achieve better health outcomes.

February 16, 2023

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the receipt of a $1.48 million payment under its contract with CPRIT.

The payment is part of a non-dilutive grant of approximately $16.1 million awarded to Salarius to support its operations and development of its drug candidate seclidemstat for the treatment of Ewing sarcoma. This $1.48 million payment brings Salarius’ cumulative disbursement from CPRIT to approximately $16.0 million.

February 15, 2023

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced expansions and updates to RADR®’s product roadmap, which will further enhance its oncology drug discovery capabilities. These RADR® advancements will focus on additional innovative AI and ML approaches to develop Antibody Drug Conjugates (ADCs), which are highly specific cancer-targeted antibodies linked to potent anti-tumor small molecules and designed for the treatment of cancer.

February 13, 2023

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced that Sulagna Bhattacharya, Chief Executive Officer and Co-Founder of Nanoscope Therapeutics, has been named to the Health Section Governing Board of the Biotechnology Innovation Organization (BIO) Board of Directors.

Ms. Bhattacharya was named to the BIO Board of Directors in February 2022 and currently serves on the Emerging Companies Section Governing Board, on which she will continue to serve in addition to her new role on the Health Section Governing Board. She has also been selected as a member of BIO’s Nominating Committee.

February 7, 2023

S&W Seed Company and Equilon Enterprises LLC (“Shell”), a global agricultural company, announced the execution of an agreement to establish a joint venture for the purpose of developing novel plant genetics for oil seed cover crops as feedstocks for biofuel production. The JV company, named Vision Bioenergy Oilseeds LLC, will be jointly owned by Shell and S&W.

February 7, 2023

Recruiting and staffing leader, Medix won ClearlyRated’s 2023 Best of Staffing Client Five Year Diamond Award, as well as Best of Staffing Talent and Employee Awards for superior client, talent and employee experience.

Fewer than two percent of all staffing agencies in the U.S. and Canada earn the Best of Staffing designation for Client and Talent Satisfaction. Fewer than one percent earn Best of Staffing for Employee Satisfaction.

February 6, 2023

PERSUIT has recognized Cooley in its 2023 PERSUIT 50 report, ranking the firm #4 among The Most Trusted Law Firms on PERSUIT’s list, which ranks firms according to the total dollar amount of matters awarded to them on the PERSUIT platform in 2021 and 2022.

Cooley LLP is an American international law firm, known for its technology and life sciences practices as well as its experience with marquee initial public offerings (IPOs) and venture capital connections & financing.

February 3, 2023

The Mark Cuban Cost Plus Drug Company, PBC and OncoPower are joining forces to build on OncoPower’s cancer care support with the launch of a Medication Savings Suite.

The collaboration leverages Cost Plus Drugs competitive pricing on generic medication to allow the cancer patients that use OncoPower to look up pricing and order less expensive medications.

February 3, 2023

JLL has been named to Fortune magazine's World's Most Admired Companies list. The list is a major authority on corporate reputations compiled each year by Fortune and Korn Ferry through a survey of global executives, directors and analysts. JLL was recognized for exceptional social responsibility and global competitiveness within the real estate industry.

Clients and third-party organizations continue to recognize JLL globally for its ethics, corporate citizenship and commitment to being an employer of choice.

January 31, 2023

Arugula Sciences announced that it has received clearance from the FDA for its investigational new drug (IND) application for a Phase 1, open-label, dose-ranging clinical trial of SIG002, a perinatal-derived secretome product. This trial will assess the safety, tolerability, preliminary efficacy, and dose effect of SIG002 in patients with symptomatic osteoarthritis of the first metatarsophalangeal joint.

January 31, 2023

It has been 361 years since anyone has seen a dodo, the odd-looking bird that has become a poster child for extinction. But Colossal Biosciences is hoping to bring them back.

Colossal Biosciences has made headlines less than 18 months ago with its announcement it planned to revive the woolly mammoth, says it will pursue the de-extinction of the iconic bird, using (in part) funds from a Series B funding round that injected another $150 million into the company.

January 30, 2023

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for the treatment of Stargardt disease to improve visual function.

January 26, 2023

MedCognetics, Inc., founded in early 2019, has developed an unbiased advanced imaging algorithm that leverages AI and Machine Learning (ML) to detect the earliest manifestations of cancer in all ethnicities, announced it has received a $750,000 grant from the National Institute of Health’s (NIH) Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity, or AIM-AHEAD program. The company is a subaward from the University of North Texas Health Science Center (HSC) at Fort Worth, Texas.

January 25, 2023

NemaLife Inc., as a TechBio company, is delighted to announce that we have advanced the capabilities of our high-throughput organism-on-chip screening platform.

NemaLife’s platform has been validated with diverse ingredients, including phytochemicals, prebiotics, probiotics, postbiotics, dietary proteins, cannabinoids, small-molecule drugs, and synthetic peptides. “We have validated our platform with 400+ ingredients. INFINITY 2.0 will open new opportunities for discovery, and we encourage companies to engage with us to accelerate their product development,” says Dhaval Patel, PhD, Director of Research and Innovation.

January 19, 2023

Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that the company has closed a senior secured term loan providing up to $400 million in capital from OrbiMed and Braidwell. With this funding, Caris has raised approximately $1.7 billion in capital since 2018.

January 18, 2023

NemaLife has been chosen as one of three Probiota Pioneers and will participate in the IPA World Congress + Probiota 2023 event in Barcelona next month.

The company provides a patented, rapid, high throughput in-vivo screening platform using the tractable microscopic worm C. elegans. While the C. elegans are one of the earliest lifeforms on the planet, there's a lot of biology that's conserved from the worm all the way up to humans meaning the platform can provide human health-relevant endpoints focused on gut health, muscle health, anti-obesity, cognitive health, stress resistance and anti-aging.

January 17, 2023

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced it has received guidance from the United States Food and Drug Administration (FDA) on Lantern’s clinical development plans for its LP-184 program.

LP-184 has shown nanomolar potency across a range of cancers including several solid tumors and multiple adult and pediatric central nervous system (CNS) cancers. The FDA feedback clears Lantern’s path for an IND submission and the targeted initiation of a first-in-human clinical trial in Q2 2023.

January 10, 2023

HR Tech Outlook magazine has named EisnerAmper Wealth Management and Corporate Benefits as one of its “Top 10 Employee Benefits Service Companies” for 2022.

“We’re glad to feature EisnerAmper as one of 2022’s Top 10 Employee Benefits Service Companies. The company’s goal is to help those we serve to best understand complex ideas and concepts so clients can benefit by applying what they communicate to help clients achieve their best financial life,” said Hanna Wilson, Managing Editor of HR Tech Outlook Magazine.

January 10, 2023

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics. Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene insertion by single vector delivery of gene editing and DNA cargoes.

January 10, 2023

Medix Infusion has closed a $35 million Series B funding round led by Echo Health Ventures. Medix provides infusion and injectable therapy to chronically and acutely ill patients at home or in one of its many ambulatory infusion centers.

The company says it will use the funds to support organic growth and acquire the infusion operations of the Center for Neurology and Spine, a national leader in the treatment of neurological disorders that serves patients across five infusion suites in Arizona.

January 10, 2023

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced that it will receive a strategic investment from the Cystic Fibrosis Foundation (CF Foundation) to develop ReCode’s inhaled mRNA-based therapeutic for people with cystic fibrosis (CF), including those with genotypes that do not respond to approved CFTR modulators.

The CF Foundation will contribute up to $15 million including an initial equity investment of $10 million to support preclinical studies needed for an Investigational New Drug (IND) application and early clinical development of ReCode’s CFTR mRNA therapy for CF. The investment includes a commitment by the CF Foundation to invest another $5 million upon completion of development milestones.

January 9, 2023

Caris Life Sciences, the leading molecular science, artificial intelligence (AI) and machine learning technology company actively developing and delivering innovative solutions to revolutionize healthcare, and ConcertAI, the leading oncology real-world evidence data and AI technology company, announced a unique partnership to align the two companies’ oncology capabilities. The collaboration creates one of the largest translational and clinical development research platforms aimed at supporting and accelerating biopharmaceutical drug development and novel therapeutic research.

January 6, 2023

With nearly $40 billion in deal volume during the fourth quarter of 2022 and over $176 billion in deal volume for the year, Cooley’s M&A practice earned the firm top recognitions on the Bloomberg, Mergermarket and Refinitiv regional and global year-end M&A and private equity league tables.

Cooley’s world-class transactional team has worked on 1,600+ M&A deals for an aggregate value of more than $760 billion since 2018 and has guided top companies and private equity sponsors in some of the market’s largest and most complex transactions. The 180+ member M&A group spans 18 major business and technology centers in the US, Asia and Europe and represents all categories of participants in transactions.

January 5, 2023

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces that on December 27, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,535,603, titled “Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides and Methods of Treating Medical Disorders Using Same.” The issued claims cover the composition of matter for novel molecular glue degraders including Salarius’ preclinical cereblon-binding compound, SP-3204, through September 2037.

January 5, 2023

Arugula Sciences, LLC, announced that it has, in collaboration with its clinical partners, advanced its first therapeutic product, Signature Cord Prime™ (SIG001), with FDA approval for a Phase 1 clinical trial (NCT05234489) in the US.

Signature Cord Prime™ is the first human umbilical cord allograft product to receive FDA approval to be studied as an intra-articular injection to treat the signs and symptoms of knee osteoarthritis.

January 5, 2023

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that the U.S. Food and Drug Administration (FDA) has granted LP-284 Orphan Drug Designation (ODD) for the treatment of mantle cell lymphoma (MCL).

January 5, 2023

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced an expansion of their collaboration to research, develop and commercialize novel XmAb® bispecific and multi-specific antibodies directed against novel targets, identified and proposed by Caris, for the treatment of patients with cancer.

January 5, 2023

Island Pharmaceuticals Ltd could begin a Phase 2a PEACH clinical trial of its dengue prevention and treatment drug ISLA-101 as early as this month, according to MST Access Research.

ILA’s strategy is to focus on repurposing drugs for viral illnesses. The strategy potentially brings advantages including lower development costs, faster timelines and lower risk.

January 4, 2023

OncoNano Medicine, Inc. announced that its lead clinical development candidate, pegsitacianine, a pH-sensitive fluorescent nanoprobe for image-guided cancer surgery, has received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) as an adjunct for the visualization of metastatic disease in the peritoneal cavity in patients undergoing cytoreductive surgery.

January 3, 2023

Trigall Genetics, the world leader in wheat biotechnology co-owned by Bioceres Crop Solutions and Florimond Desprez, and S&W Seed Company, a leading middle-market agricultural company, have entered into a joint venture to advance wheat breeding activities in Australia.

Mark Wong, CEO of S&W Seed added: “We are excited to enter this JV to combine our commercial footprint with the unique technologies and expertise of our partners.”

December 28, 2022

Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd is pleased to announce that that the Investigational New Drug (IND) application for the ISLA-101 Phase 2a PEACH clinical trial has been filed with the United States Food and Drug Administration (US FDA).

December 20, 2022

Scorpion Biological Services announced it has changed its name to Scorpius BioManufacturing reflecting the company’s recently expanded manufacturing capabilities and the grand opening of its new biomanufacturing facility in San Antonio in October.

The new facility offers GCP, GLP and GMP biomanufacturing capabilities in both mammalian and microbial modalities. Suites and equipment trains are flexible, with bioreactor sizes ranging from 50 L up to 2,000 L, and best-in-class equipment installed across the facility to produce high-quality material for clients. Scorpius offers the capability to manufacture a wide range of products, including cell therapy, recombinant proteins from mammalian or microbial systems, and DNA vectors.

December 20, 2022

The current advent of artificial intelligence (AI) is shaping the evolution of entire industries, including the pharmaceutical and biotech industries. Unsurprisingly, almost every large and small Life Science organization has shown keen interest in adopting AI-driven discovery platforms in the hope of streamlining R&D efforts, reducing discovery timelines and costs, and improving efficiency.

For example, Lantern Pharma, a US-based clinical-stage biotechnology company, focused on innovating the cancer drug development process by using advanced genomics, machine learning, and artificial intelligence. The company’s AI platform, RADR®️, currently includes more than 25 billion data points and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then to identify relevant cancer patient subgroups to benefit from Lantern’s drug candidates.

December 13, 2022

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that it has expanded development of its drug candidate LP-184 to include Triple Negative Breast Cancer (TNBC), one of the most aggressive and malignant forms of breast cancer. New positive preclinical data on the anti-tumor potency of LP-184 for TNBCs was recently presented at the San Antonio Breast Cancer Symposium (SABCS) 2022.

December 9, 2022

Mark Cuban Cost Plus Drug Company will offer prescription drug discounts to self-insured employers via a new platform called EmsanaRx Plus.

Cuban's drug company is partnering with pharmacy benefits manager EmsanaRx to expand access to lower-cost medicines to employers and employees. For Cost Plus Drugs, the partnership marks a strategic shift from operating exclusively in the direct-to-consumer market into the employer market.

December 8, 2022

Introducing NextLeap - a revolutionary new cosmetic product designed to address cold sores using the ground-breaking Tranexamic Acid that addresses skin discoloration.

“If cold sore treatments have not worked for you as well as you hoped, applying NextLeap underneath a topical cold sore therapy should provide you with a much faster return to normal appearance and let you get back to your life.” Co-Founder, Frank Murdock explains, “Our mission is to give peace of mind for the one in four people who are affected by cold sores so they can get back to looking like themselves sooner.”

December 6, 2022

Servant leadership lies at the heart of our choice for this year’s Contractor of the Year. TDIndustries’ management philosophy can best be summed up as focusing on the needs of others. Most businesses naturally tune into their customers’ needs. But a servant leader also extends that attention to the staff, going so far as to flip the typical organizational chart 180 degrees.

Being a servant leader, however, and making money in the process aren’t mutually exclusive.

TDIndustries, based in Dallas and with operations throughout Texas, Arizona and Colorado, has done just that – and done it for 76 years.

December 6, 2022

Good Days announced a referral partnership with Dollar For, a nonprofit organization that helps reduce or eliminate medical bills from nonprofit hospitals.

"The financial toll of an illness comes in many different forms, whether it be hospital bills, premiums or the cost of treatments," said Clorinda Walley, president of Good Days. "We're glad to collaborate with Dollar For to help our community access additional resources and financial assistance so that they can focus on their personal wellbeing, not their finances."

December 6, 2022

Caris Life Sciences, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced a strategic collaboration to advance clinical development of Hummingbird Bioscience’s anti-HER3 therapy, HMBD-001.

“Our partnership will help evaluate biomarkers to better understand the clinical utility for this novel therapy, drive patient recruitment and clinical trial access, and may ultimately provide new treatment alternatives and options to patients who are not responding to current therapies” said Brian Lamon, Ph.D., Chief Business Officer at Caris Life Sciences.

December 5, 2022

NutraIngredients was on the hunt for entrepreneurial consumer-facing, science or technology-based start-ups to join them at the IPA World Congress + Probiota 2023 in Barcelona next February.

NemaLife has been selected as the 2023 Probiota Pioneer winner.

December 1, 2022

The National Association of Chain Drug Stores (NACDS) Foundation celebrated its 24th Annual Foundation Dinner in New York City on November 30. The event raised more than $1.5 million, which will help support evidence-based research, pharmacy education and philanthropic initiatives to improve patient outcomes and advance population health.

Brett Giroir, MD was presented with the NACDS Foundation’s 2022 Excellence in Patient Care Award at the 24th Annual NACDS Foundation Dinner. Dr. Giroir was recognized during the event for his extraordinary leadership on the front lines of the COVID19 response and for his unwavering focus on access and equity.

November 25, 2022

Island Pharmaceuticals has announced that its ISLA-101 (fenretinide) capsules have passed the analytical testing stage.

ISLA-101 is a repurposed drug with extensive data to support its safety profile. The Phase 2a trial is expected to commence in January 2023, under the assumption there are no queries from the FDA.

November 22, 2022

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that it presented positive preclinical data on the efficacy of its drug candidate LP-184 for glioblastoma (GBM), used alone or in combination with the Food and Drug Administration (FDA) approved agent spironolactone, at the Society for Neuro-Oncology (SNO) annual meeting.

View full version of the poster presentation here.

November 16, 2022

Island Pharmaceuticals Ltd is pleased to announce that a key patent relating to the Company’s lead drug candidate, ISLA-101, has been granted by the Canadian Intellectual Property Office (CIPO).

The patent covers a method of treating or preventing dengue virus or other mosquito borne virus infections with ISLA-101.

November 16, 2022

The governing board of the Cancer Prevention and Research Institute of Texas (CPRIT) approved $12 million in recruitment grants in its quarterly meeting at the Texas Capitol on Wednesday. The grants will bring two CPRIT Scholars from out-of-state institutions to Texas to expand their cancer research and add to the state’s growing cancer research prowess.

November 14, 2022

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced the formation of the company’s scientific advisory board (SAB) and the addition of scientific advisor, Elliott Sigal, M.D., Ph.D. Chaired by Daniel J. Siegwart, Ph.D., inaugural members of the SAB include Rafael Amado, M.D., Carrolee Barlow, M.D., Ph.D., Justin Hanes, Ph.D. and Eric Olson, Ph.D.

These advisors will work closely with management to support the company’s expansion of its selective organ targeting (SORT) lipid nanoparticle (LNP) platform capabilities and advance its pipeline.

November 14, 2022

Island Pharmaceuticals Ltd is pleased to announce that ISLA-101 capsules for use in the upcoming Phase 2a PEACH clinical trial in dengue fever have completed analytical testing, further demonstrating the viability of the material for use in the trial.

Following investigation of batch capsule samples, it has been confirmed that the capsules have excellent content uniformity, which is a measure of the consistency of the level of active ingredient in each of the capsules.

November 10, 2022

OncoNano Medicine, Inc. announced the presentation of data on its pre-clinical candidate ONM-501 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, Massachusetts. ONM-501, OncoNano’s lead therapeutic program in development, is a dual-activating STING (Stimulator of Interferon Genes) agonist advancing towards a first in human trial planned to be initiated in the first half of 2023.

November 7, 2022

Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, announced that the Company has expanded its clinical and Chemistry, Manufacturing and Controls (CMC) team with the appointments of Jean Chang, as VP of Clinical Operations and Victor Adeniyi as Senior Director of CMC.

“We are excited to welcome Jean and Victor, both experienced biopharmaceutical leaders in gene therapy, to the Nanoscope team, and we look forward to the integral roles they will play in bolstering our clinical and CMC capabilities,” said Sulagna Bhattacharya, CEO of Nanoscope.

November 2, 2022

J.P. Morgan Asset Management launched a new life sciences-focused private equity team, dubbed Life Sciences Private Capital, to support early- and growth-stage biotech companies.

In particular, the Life Sciences Private Capital team will focus on innovative therapies and technologies in neuropsychology, metabolic diseases, artificial intelligence, autoimmunity, genetic medicine, oncology, rare diseases and neurodegenerative diseases.

October 30, 2022

“We’re all taught how to take care of our skin and our nails,” said Elyse Dickerson. “But we’re not taught at a young age how to take care of our ears.” The co-founder and CEO of Eosera, a female-led brand committed to solving an unmet need in the field of ear health, spent 13 years in the OTC healthcare industry before branching out on her own to solve a large, but often unspoken, need in a very niche market. Ear wax removal.

October 24, 2022

Astellas Pharma Inc. and Taysha Gene Therapies, Inc. announced a strategic investment to support the advancement of Taysha’s adeno-associated virus (AAV) gene therapy development programs for the treatment of Rett syndrome and GAN. The future options to potentially apply Astellas’ global R&D, manufacturing and commercialization capabilities in gene therapy to Taysha’s innovative AAV gene therapy development programs for genetic diseases of the central nervous system (CNS) create the opportunity for the two companies to enhance the development of novel treatment options for patients with Rett syndrome and GAN, who have serious unmet medical needs.

October 20, 2022

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,471,431, for Lantern’s drug candidate LP-300, which is in a Phase 2 clinical trial, Harmonic™, for never-smokers with relapsed non-small cell lung cancer (NSCLC).

October 17, 2022

The National Association of Chain Drug Stores (NACDS) Foundation will bestow its highest honor to a physician-scientist and innovator whose career has been dedicated to improving public health and medicine — and whose public service during the COVID-19 pandemic contributed mightily to America’s health and recovery. Brett P. Giroir, MD, is the recipient of the 2022 Excellence in Patient Care Award and will accept the award at the 24th Annual NACDS Foundation Dinner on November 30, 2022, in New York City.

October 13, 2022

GL Chemtec International has been selected by the Canadian Business Review Board as "Best Businesses in Canada" for the second year in a row! The Canadian Business Review Board has a mission of identifying and promoting consumer-centric businesses across North America. GL Chemtec is committed to providing our clients with innovative solutions and technologies.

October 11, 2022

The Central Intelligence Agency (CIA) has invested in Colossal through its nonprofit VC investment arm, In-Q-Tel.

So why did In-Q-Tel invest in Colossal? “Strategically, it’s less about the mammoths and more about the capability,” they write. “The next wave of progress in synbio will lead to advances in our ability to shape both form and function in organisms at the macroscopic level.”

October 6, 2022

Nanoscope Technologies LLC, a biotechnology company developing gene therapies for treatment of chronic diseases, announced that it has received $1.5 Million SBIR Direct-to-Phase II grant from NIH in support of its advancement of glaucoma therapy using Engineered Mechanosensitive Channel (EMC).

The Nanoscope team has developed EMCs to sensitize cells toward abnormal mechanical stress related to pressure elevation caused by Glaucoma. SBIR Direct-to-Phase II grant award is based on demonstration of feasibility of the technology equivalent to meeting Phase I objectives and providing a solid foundation for the proposed Phase II activity.

October 4, 2022

The High-Risk, High-Reward Research program, supported by the Common Fund at the National Institutes of Health has awarded 103 new research grants to support highly innovative scientists who propose visionary and broadly impactful meritorious behavioral and biomedical research projects.

The High-Risk, High-Reward Research program supports investigators at each career stage who propose innovative research that, due to their inherent risk, may struggle in the traditional NIH peer-review process despite their transformative potential. Investigators seeking program support are encouraged to think beyond traditional bounds and to pursue trailblazing ideas in any area of research relevant to the NIH’s mission to advance knowledge and enhance health.

October 4, 2022
NemaLife Inc., a techbio company focused on high throughput in vivo screening, is delighted to announce that it has joined the International Probiotic Association (IPA). This global non-profit organization brings together various stakeholders in the probiotic sector to promote the safe and efficacious use of probiotics for human health and wellbeing.

September 29, 2022

OncoNano Medicine, Inc. announced positive interim clinical results from an ongoing Phase 2 study of its lead clinical development candidate, pegsitacianine, for the detection of residual disease following cytoreductive surgery (CRS).

The interim results from this trial provide evidence that pegsitacianine could offer surgeons a real-time optical imaging capability that enhances their ability to detect residual cancerous tissue that would otherwise be left behind from their standard of care process for cytoreductive surgery of peritoneal metastases.

September 27, 2022

Dallas-based Colossal Biosciences, the self-described de-extinction company behind the woolly mammoth and thylacine, announced that it is spinning off Form Bio, as an independent software company offering a computational life sciences platform that bridges the gap between data and discovery.

Driven by deep learning artificial intelligence (AI) algorithms, Form Bio empowers life scientists with a software platform for managing large datasets, executing verified workflows, visualizing results and collaborating with their peers. The platform brings these capabilities together in one cohesive unit with a user experience designed to simplify computational work and bolster life science breakthroughs across companies, labs and universities.

September 27, 2022

NemaLife Inc., a techbio company focused on high throughput in vivo screening, is delighted to announce that it has received funding from the National Institute of Drug Abuse (NIDA). This new funding of $320,000 enables NemaLife to partner with companies in the growing psychedelic market by expanding the capabilities of its technology platform to screen for therapeutics for neurobehavioral disorders using a tractable biological model, the worm C. elegans.

September 26, 2022

The Horizons: Life Sciences report is the third in a series of CRB’s survey-based Horizons explorations of critical trends in the life sciences industry.

The report features perspectives from nearly 500 industry leaders representing North American, European, and multinational companies, primarily from R&D roles upstream of GMP manufacturing. The new report finds that companies are investing in novel research, pushing beyond traditional comfort zones, and moving cautiously but unwaveringly toward an advanced standard of care for critically ill patients.

September 23, 2022

Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced a partnership with Flatiron Health, a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients, to integrate Caris’ market leading molecular testing portfolio with OncoEMR®, a leading cloud-based electronic medical record (EMR) tool.

September 19, 2022

EisnerAmper was named the “Best Auditor — Middle Market” at the HFM U.S. Services Awards 2022, which were held on September 13 in New York City.

The prestigious HFM U.S. Services Awards recognize hedge fund service providers that have demonstrated exceptional client service, performance and innovation over the past 12 months.

September 15, 2022

CAGE Bio Inc., a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology and TAGCyx Biotechnologies Inc., a biotechnology company developing DNA aptamer drugs based on its proprietary artificial nucleic acid base pair technology, announce the execution of a license agreement for development of TAGX-0003 for the targeted treatment of alopecia areata and vitiligo by dermatological application. PeptiStar Inc., a technology-based contract development and manufacturing organization (CDMO) for peptide and oligonucleotide APIs, will manufacture TAGX-0003 for the development and possible future commercialization.　

September 14, 2022

The Oversight Committee of the Cancer Prevention and Research Institute of Texas (CPRIT), held a special meeting to approve a slate of awards totaling $48,923,075 for cancer research and product development.

Among the priorities addressed in today’s awards is over $23 million for core facilities, almost $6 million for expanding access to clinical trials, $8 million for computational oncology, $22 million for cancer-fighting drug discovery and over $17 million for childhood cancer research.

September 13, 2022

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced full enrollment of its Phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for Stargardt disease. Six-month data from the Phase 2 STARLIGHT trial are expected in H1 2023.

“We are excited by the therapeutic potential of MCO-010, supported by robust data from previous preclinical and clinical studies,” said Sulagna Bhattacharya, CEO of Nanoscope. “Completing the quick two-month enrollment of this Phase 2 trial, which will evaluate the safety and effects of a single intravitreal injection of MCO-010, brings us another major step forward in developing this novel therapy with broad therapeutic application.”

September 12, 2022

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech’s 20th annual Fierce 15 selection. An internationally recognized daily report reaching a network of over 450,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

August 25, 2022

The University of Texas Board of Regents today approved an allocation of $100 million in Permanent University Fund (PUF) bond proceeds over the next 10 years that will help fund capital expenses associated with the start-up of the Tyler School of Medicine at the University of Texas at Tyler.

“The opportunity for the regents to invest again in this once-in-a-generation opportunity to improve the quality of life and health for the people of East Texas is gratifying,” said Kevin P. Eltife, Chairman of the UT System Board of Regents. “We are equally as focused on the future of the medical school as we are on the present, and we enthusiastically await the arrival of the first class of medical students in Tyler next summer.”

August 24, 2022

CPRIT invests in startup and early-stage companies in Texas (and those willing to relocate to Texas) to foster development of novel cancer therapeutics, medical devices, diagnostics, tools and other non-traditional oncology products.

CPRIT announces the release of four (4) Requests for Applications (RFAs) for FY 2023 Product Development Research grants.

August 23, 2022

Cancer Insight, an oncology-focused clinical research organization (CRO), today introduced a new corporate identity: LumaBridge. As LumaBridge, the company will continue to build on its legacy of supporting the development of novel immunotherapies in the fight against cancer.

August 23, 2022

LumaBridge (formerly known as Cancer Insight), an oncology-focused clinical research organization (CRO), announced a majority growth investment from global investor Summit Partners. The funding will help LumaBridge continue to build on its work offering best-in-class clinical trial solutions to support emerging biopharma companies that are working to develop life-changing immuno-oncology treatments.

August 22, 2022

Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from a bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).

Cedric O’Gorman, MD, Chief Medical Officer of Alpha Cognition, commented, "We are delighted with these additional positive registrational bioequivalence results from our second study of our lead asset, ALPHA-1062, which further strengthens our NDA filing. We have successfully demonstrated that ALPHA-1062 is bioequivalent to two different release formulations of galantamine hydrobromide, the immediate release and the extended release. ALPHA-1062, a prodrug of galantamine, was designed to limit gastrointestinal side effects and, if approved, could provide a meaningful advancement for patients with Alzheimer’s Disease.”

August 17, 2022

The Oversight Committee of the Cancer Prevention and Research Institute of Texas (CPRIT), approved a large slate of awards totaling over $89 million for cancer research, prevention and product development.

“The awards approved today by the Oversight Committee illustrate the depth and breadth of CPRIT's impact in the Texas fight against cancer,” said CPRIT CEO Wayne Roberts.

 “From recruitment grants bringing the brightest cancer researchers to Texas, to supporting lifesaving prevention programs across the state and providing critical investments in developing new cancer-fighting drugs, CPRIT touched all the bases for a home run against cancer."

August 15, 2022

Colossal Biosciences is using state-of-the-art genomic sequencing and Crispr gene-editing technologies to splice together recovered genetic material from the long-lost mammoths and DNA from Asian elephants.

Climate change led to the extinction of the woolly mammoth, but reintroducing them to the wild could re-establish balance and biodiversity in certain biomes.

And as global temperatures rise, the melting permafrost could unleash even more greenhouse gases, exacerbating global warming. Herds of woolly mammoths could help tamp down the tundra and prevent that from happening.

August 12, 2022

GL CHEMTEC (“GLC”), a specialist in advanced chemistry R&D and scale-up services to support Active Pharmaceutical Ingredient (“API”) development, and the development of advanced materials for drug delivery, medical devices, and other life science applications, today announced it is partnering with Edgewater Capital Partners (“Edgewater”), a lower middle-market private equity firm with deep sector expertise in Life Sciences and Pharma Services, accelerating the company’s growth as a leading North American chemistry-based contract research organization (CRO).

August 16, 2022

Colossal Biosciences—the Dallas-based company attempting to revive the woolly mammoth—has announced that it has started working on the de-extinction of the thylacine, better known as the Tasmanian tiger.

One of Australia's most iconic species, the thylacine population declined dramatically on the mainland, likely as a result of hunting by humans and competition with the dingo, leading to its disappearance there at least 2,000 years ago, according to the Australian Museum.

August 16, 2022

Inc. revealed that TimelyMD is No. 116 on its annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America.

This was the first year of eligibility for Fort Worth-based TimelyMD, the leading virtual health and well-being solution in higher education. Founded in 2017, TimelyMD demonstrated significant three-year revenue growth from 2018 to 2021, ranking it No. 4 in the Dallas-Fort Worth area, No. 6 in Texas and No. 9 in the health services sector.

August 9, 2022

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that on August 8, 2022, after the U.S. financial markets closed, we received a communication from the U.S. Food and Drug Administration (FDA) informing us that they have extended the review timeline for the New Drug Application (NDA) for omaveloxolone for the treatment of Friedreich’s ataxia by three months.

“We are pleased with the FDA’s decision to review the new information we recently provided to the Division,” said Warren Huff, Reata’s Chief Executive Officer. “We remain committed to our goal of working with the FDA to secure regulatory approval for omaveloxolone as quickly as possible for patients with this severe disease that has no approved therapies.”

August 4, 2022

Dallas philanthropist Lyda Hill is among five distinguished recipients of the 2022 Carnegie Medal of Philanthropy. An early donor of the research that led to the Moderna COVID-19 vaccine, Hill believes that "science is the answer"—and has chosen to donate the entirety of her estate to philanthropy and scientific research.

“The 2022 Carnegie Medal of Philanthropy honorees have a wide range of important priorities, yet they share a common goal through their determination to have impact and create positive change,” said Governor Thomas H. Kean, chairman of Carnegie Corporation of New York’s board of trustees and former governor of New Jersey.

The medal—one of the most prestigious honors in philanthropy—aims to inspire a culture of giving by honoring innovative philanthropists and elevating the importance and relevance of philanthropic contributions to our world.

August 2, 2022

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, today announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition’s Nu.Q® technology to support further development of Salarius’ clinical stage drug, seclidemstat.

“We are delighted to collaborate with Volition and believe its Nu.Q® technology may provide valuable biomarker information as we seek to advance the development of seclidemstat in multiple clinical indications,” commented David Arthur, CEO of Salarius. “Biomarkers allow for a noninvasive method for determining target engagement and potential drug activity in patients. So, this exciting research collaboration with Volition Rx Limited provides another tool to aid in the development of seclidemstat in clinic.”

August 2, 2022

Caris Life Sciences and Xencor, Inc. announced a multi-year strategic option and license agreement to research, develop and commercialize XmAb® bispecific antibodies directed against novel targets for the treatment of patients with cancer. Under the terms of the agreement, Caris will apply its proprietary end-to-end discovery platform, Caris Discovery, to identify novel targets for bispecific antibody drug candidates.

“Consequently, we have launched a comprehensive platform agnostic to therapeutic modality to discover and validate novel cancer targets. Our collaboration with Xencor will combine Caris’ proprietary, multi-omics target discovery engine and Xencor’s XmAb engineering platform to design and manufacture investigational bispecific antibodies to develop first-in-class therapies for patients with cancer.”

August 1, 2022

AyuVis Research, Inc. has been selected for MassChallenge’s 2022 U.S. Early-Stage Cohort, a premier global accelerator program.

AyuVis compounds are projected to revolutionize the prevention and treatment of life-threatening inflammatory diseases. More than 1,300 premature babies die in the U.S. every year because of chronic lung injury caused by inflammation, and according to the CDC’s National Vital Statistics Report on U.S. Births in 2019, at least half of premature babies are from underserved communities. AyuVis is pioneering innovative immunotherapies via recharging the innate immune system with a goal of saving and improving the lives of these premature babies.

July 26, 2022

ENR’s annual Sourcebook – considered among the most-respected rankings within the AEC space – listed CRB as the no. 2 provider of pharmaceutical manufacturing design, up from no. 3 in 2021. The company held on to its no. 4 ranking for industrial process work, and was ranked 8th among food and beverage manufacturing service providers.

Additionally, ENR’s recent list of top design-build firms ranked CRB among the United States’ top 50. The company came in at no. 36, up eight spots from 44 in 2021. Earlier this summer, ENR’s 2022 Top 500 Design Firms list ranked CRB among the top 100. Ranked according to revenue for design services performed in 2021, CRB came in at number 67 – up from no. 101 the year previous.

July 25, 2022

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the first patient has been dosed in a Phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy for Stargardt disease.

“This trial represents the second indication for our vision restoring therapy for people blinded by rare inherited retinal degenerative diseases regardless of gene mutations,” said Sulagna Bhattacharya, CEO of Nanoscope.

July 21, 2022

When The University of Texas Health Science Center at Fort Worth received a $562,500 grant, managers of the Sparkyard platform that supports local entrepreneurs and startups set out to expand its services. One of the key initiatives of that expansion was to translate Sparkyard into Spanish and embark on a significant outreach to Fort Worth’s Spanish-speaking entrepreneurial community.

Sparkyard (www.sparkyard.co) and its vast array of resources, is now available in Spanish on a separate site. The free platform helps both new and existing companies in Tarrant County connect to the right resource at the right time to launch and grow.

Sparkyard provides a variety of free services to entrepreneurs in the Fort Worth area, including customized Spark Plans to help businesses overcome current obstacles, a comprehensive regional events calendar, a directory of free business-building resources, local economic research, ways to identify resource gaps and more.

July 14, 2022

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that the Food and Drug Administration (FDA) has cleared the Company to proceed with its Phase 2 clinical trial, Harmonic™, for its investigational new drug LP-300.

The Harmonic™ trial will be a 90 patient, multi-center, two arm, open-label, and randomized clinical trial evaluating LP-300 in combination with chemotherapy for never smoker patients with advanced non-small cell lung cancer (NSCLC).

July 14, 2022

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced that the Company was chosen for Breakthrough Technologies Award at OIS Retina Innovation Summit in New York. The award is granted to a single company that demonstrates groundbreaking technological innovation, selected by Medical and Industry Peers.

July 14, 2022

The TCU School of Medicine will expand more than its walls in the coming years, the school’s dean, Dr. Stuart Flynn, told a small group of real estate and banking personnel on July 13. Specifically, the school will soon serve as the epicenter for a clinical trials research consortium in Fort Worth.

The consortium, right now a partnership between the medical school and three area hospitals, will encourage pharmaceutical and biotech companies to open trials for people in the city, Flynn said.

July 7, 2022

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, announced an enhanced partnership with Epic, a leader in software systems for electronic health records (EHR), to integrate Caris’ market leading molecular testing portfolio with Epic’s Orders and Results Anywhere (ORA) network.

The ORA network integration, available later this year, is an important next step to fully enabling data-driven decision making for Epic system users, which represents 60% of oncologists in the U.S. By integrating test ordering and resulting directly into Epic ORA, Caris can streamline clinical workflows for physicians and offer access to structured genomic data all within their Epic environment.

June 30, 2022

The annual BIO conference is the world’s largest, regularly attracting 15,000 to 20,000 attendees each year before the pandemic. The recent San Diego conference was the first time BIO International was held fully in person since the pandemic began.

“We received interest from a half dozen bio companies to relocate to the Dallas region,” Kevin Shatley, VP of Economic Development for the DRC, said in the statement.

The interested companies included pre-clinical and clinical stage therapeutic companies, along with others providing industry-specific services.

“They recognize the area’s emergence in life sciences, which is driven by our strengths in biosciences, data science, artificial intelligence, logistics, financial technology, blockchain, and sensors and microprocessors,” Shatley added.

June 29, 2022

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of messenger RNA (mRNA) and gene correction therapeutics, today announced the close of a Series B extension financing round, co-led by new investors, Leaps by Bayer, the impact investment unit of Bayer AG, AyurMaya, an affiliate of Matrix Capital Management, and with participation from Amgen Ventures. With the additional $120M in new financing, the company has secured a total of $200M in Series B funding.

June 27, 2022

Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that CEO and Co-Founder Sulagna Bhattacharya has been named a winner of Ernst & Young's Entrepreneur Of The Year® 2022 Central Plains Award. She is among 11 regional winners from 46 Central Plains finalists.

June 23, 2022

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries has entered into an agreement with GeminiBio to deliver custom hydrated solutions and cell culture media to the biopharma industry.

This collaboration will complement Avantor's proven ability to serve manufacturing platforms with GeminiBio's small-to-medium scale offering, enabling customers to utilize custom cGMP products through the full development lifecycle – including early-stage research, scale-up and commercialization.

June 22, 2022

Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from its pivotal bio-equivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).

Cedric O’Gorman, MD, Chief Medical Officer of Alpha Cognition, commented, "We are very pleased with the positive results from the current studies of our lead asset, ALPHA-1062. If approved, ALPHA-1062 could provide a meaningful advancement for patients with Alzheimer’s Disease, especially those who are unable to tolerate the gastrointestinal side effects that often occur with many of the current treatment options.”

June 21, 2022

BioLabs Pegasus Park announces that Aakha Biologics, an inaugural tenant, has successfully taken the next step in its development by relocating to permanent headquarters in Frisco, Texas.

“Our time at BioLabs Pegasus Park proved to be an ideal situation for us. We had excellent opportunities to interact with colleagues and like-minded entrepreneurs,” said Hemanta Baruah, PhD, founder and CEO of Aakha Biologics.

“Aakha Biologic’s commitment to locate and grow in North Texas signals the region’s strong biotech commercialization potential. Operations here in North Texas are supporting promising life science startups that will change the world and benefit mankind,” said BioLabs Pegasus Park’s Site Director, Gabby Everett, PhD.

June 15, 2022

Nacuity Pharmaceuticals focuses on ocular diseases caused by oxidative stress in the retina, including age-related macular degeneration, glaucoma, and diabetic retinopathy. The $16.5M funding, led by the Foundation Fighting Blindness, will help advance two Nacuity clinical trials.

June 13, 2022

Alpha Cognition Inc., a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the discovery of two GEM combinations, ALPHA-0702 and ALPHA-0802, and positive preclinical data from each candidate therapy.

ALPHA-0702 and ALPHA-0802 are Granulin Epithelin Motifs, or GEMs, derived from full length progranulin (PGRN) which have therapeutic potential across multiple neurodegenerative diseases. GEMs have been shown to be important in regulating cell growth, survival, repair, and inflammation.

ALPHA-0702 and ALPHA-0802 have demonstrated robust results in a recent preclinical study, leading the Company to believe in the future potential of this platform to develop therapeutics to treat a wide array of diseases.

June 8, 2022

Fifteen scientists in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern received more than $17 million in research funds in the latest round of grants awarded by the Cancer Prevention and Research Institute of Texas (CPRIT). The grants will be used to address scientific questions covering a wide range of cancer types and topics.

June 6, 2022

American entrepreneur and investor Mark Cuban launched the Mark Cuban Cost Plus Drug Company (MCCPDC), a public-benefit corporation and online pharmacy that provides patients access to medications at a lower cost.

US drug prices have soared over the last several decades, causing, at times, financial hardship for patients and their families, so Cuban says he developed MCCPDC with a simple mission – “to be the low-cost provider of medications to patients.”

June 3, 2022

Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today introduced its Caris Assure™ liquid biopsy assay at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Booth #22081).

With Caris Assure, we have created the most extensive sequencing assay available to ensure we leave no stone unturned in properly guiding treatment selection and ongoing cancer care management.

June 2, 2022

A scientific team, led by the scientific founders of EtiraRx, has identified a small molecule, ERX-41, as a novel oral therapeutic agent that may have utility in treating multiple solid cancers, including triple negative breast cancer, glioblastoma, ovarian and pancreatic cancers. EtiraRx, headquartered in Biolabs Pegasus Park, plans to initiate clinical trials as early as the first quarter of 2023.

June 2, 2022

The Texas Healthcare and Bioscience Institute (THBI) will host the BioTexas booth at the 2022 BIO International Convention in San Diego, CA, June 13-16. Each year, THBI organizes a delegation from Texas to showcase the state’s thriving biotechnology and life sciences sector at the world’s largest biotechnology conference. More than 16,000 biotechnology and pharmaceutical leaders are expected to attend the annual gathering.

May 25, 2022

GeneTether Therapeutics Inc., announced that the United States Patent and Trademark Office has granted patent #11,339,385 entitled "Modified Nucleic Acid Editing Systems for Tethering Donor DNA" related to its GeneTether platform technology. The claims cover a composition of matter for tethering a donor DNA template to a fusion protein of a nuclease and the lac repressor DNA binding domain, in particular where the donor DNA includes the lac operator sequence.

May 23, 2022

Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, and Lupagen, Inc., a gene therapy company developing first-in-class gene delivery technologies for CAR-T, gene editing and immunotherapy products, today announced they have entered into a collaboration to evaluate extracorporeal in vivo delivery as a potential additional route of administration for Umoja’s VivoVec particles using Lupagen’s Side CAR-T™ technology.

May 18, 2022

The Oversight Committee, the governing body of the Cancer Prevention and Research Institute of Texas (CPRIT), has approved a slate of 17 recruitment awards for a total of almost $48 million, bringing eminent cancer researchers from across the country to Texas institutions.

“Today’s action by the Oversight Committee deepens the bench of premiere cancer research at Texas institutions,” said CPRIT CEO Wayne Roberts. “CPRIT’s mission is to invest in the research prowess of Texas institutions while expediting breakthroughs in cancer cures and prevention, and today we’ve done just that. These 17 highly respected researchers will join an impressive roster of cancer-fighters who call the Lone Star State home.”

May 17, 2022

Historically, lab and research spaces were mostly clinical and designed to support the work being done, rather than the people who work in them. This is changing, says Isabel Mandujano, Director of Laboratory Planning at LPA Inc., a sustainable design firm.

Now, fixed lab benches are becoming flexible and roll around on casters so a space can be adapted as new needs arise. Infrastructure — including electrical wiring and gas pipes — is housed in ceilings and walls with switches or valves that enable quick adjustment and reconnection in future, she says.

“The last two years have seen an explosion of emerging markets [for life sciences workplaces] in cities that previously were not even part of the picture, including Chicago, Philadelphia, Atlanta, Oklahoma City, Dallas, Houston, and Austin, where companies are willing to relocate to be able to have more affordable space,” says Mandujano.

And these new markets are increasingly calling on flexible, adaptable, modular solutions to manage explosive growth — as well as attract and retain highly sought-after talent.

May 13, 2022

AyuVis has received an official Notice of Award for a $1.8M National Institute of Health (NIH) Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

It is the third NIH/SBIR grant AyuVis has received since its founding, bringing total non-dilutive funding to $2.1M. The NICHD is one of the institutes of the NIH in the U.S. Department of Health and Human Services.

May 12, 2022

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on May 26th, 2022 at 12:00 p.m. ET. The webinar will focus on glioblastoma multiforme (GBM) and the potential of Lantern's drug candidate LP-184 for GBM as well as other brain cancers.

Virtual KOL Webinar Details:

Thursday, May 26th, 2022 at 12:00 p.m. – 1:00 p.m. ET

To register for the webinar, click here.

May 11, 2022

CAGE Bio Inc., a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology, announced dosing of the first patient in its Phase 2 clinical trial for the treatment of inflammatory lesions of rosacea.

The 12-week randomized double-blind vehicle-controlled trial is testing CAGE Bio's novel ionic-liquid based product CGB-400 Topical Gel. Patients diagnosed with moderate to severe rosacea with inflammatory lesions on their face will be enrolled in the study at four sites in the US and randomized to an active or vehicle arm.

May 10, 2022

ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) lipid nanoparticle (LNP) delivery platform, today announced that David Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat on Tuesday, May 17 from 2:05 - 2:30pm ET at the upcoming 2022 RBC Capital Markets Global Healthcare Conference being held in New York City from May 17 - 18, 2022.

May 9, 2022

S&W Seed Company will report financial results for its third quarter fiscal year 2022, ended March 31, 2022, on Monday, May 16, 2022, before the open of the market. The Company has scheduled a conference call that same day, Monday, May 16, 2022, at 11:00 am ET to review the results.

May 3, 2022

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results and operational highlights for the first quarter ended March 31, 2022.

May 3, 2022

Taysha Gene Therapies, Inc., a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it has been granted orphan drug designation from the European Commission for TSHA-120, an intrathecally dosed AAV9 gene therapy currently in ongoing clinical evaluation for the treatment of giant axonal neuropathy (GAN).

“GAN is a progressive and devastating neurodegenerative disease that has an estimated addressable patient population of 5,000 worldwide. The disease impacts a broad range of patients, with an early onset form of the disease affecting young infants, while a late onset can affect patients into adulthood,” said Suyash Prasad, MBBS, M.SC., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development of Taysha.

April 29, 2022

Today, the National Organization for Rare Disorders (NORD®) announced three new requests for proposal (RFP) for grant funding related to the following rare diseases: Autoimmune Polyglandular Syndrome Type 1 (APS-1), Levy-Yeboa Syndrome (LYS) and Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS).

The NORD Jayne Holtzer Rare Disease Research Grants Program provides seed-money grants to qualified investigators for scientific and clinical research. NORD’s program provides grants for the study of diseases for which there are few other sources of funding.

April 27, 2022

The National Institutes of Health has awarded a four-year, $2.4 million grant to The University of Texas Health Science Center at San Antonio, which will work in collaboration with the American Dental Association Science & Research Institute to conduct a clinical trial studying the responsible use of antibiotics in combination with other treatments for periodontal disease, commonly known as gum disease.

April 27, 2022

Seemal R. Desai, MD, FAAD, a member of Gore Range Capital’s Scientific Advisory Board (SAB), has been elected incoming President-Elect of the American Academy of Dermatology (AAD). His elected service to the American Academy of Dermatology will span a three-year period starting 2023 as President-Elect, President in 2024 and Immediate Past-President in 2025.

Dr. Desai is a board-certified dermatologist and a Diplomate of the American Board of Dermatology. His clinical expertise includes the treatment of vitiligo and other disorders of pigmentation, psoriasis, acne, skin disease in skin of color, cosmeceuticals, and aesthetics.

April 26, 2022

Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Maria L. Maccecchini, Ph.D. has been named as a nominee for election to Lantern's Board of Directors. Dr. Maccecchini will be presented alongside a slate of five existing Directors at Lantern's upcoming Annual Meeting to be held on June 8, 2022.

April 26, 2022

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases, today announced four presentations on the Company’s preclinical and clinical research in retinitis pigmentosa (RP) and Stargardt macular degeneration at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, being held May 1 – 4, 2022, in Denver, Colorado.

April 25, 2022

Taysha Gene Therapies, Inc., a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced oral presentations at the upcoming International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Symposium taking place in Nashville, Tennessee April 26 – 27, 2022, and the ASCEND Rett Syndrome National Summit taking place in Nashville, Tennessee April 27 – 30, 2022.

April 22, 2022

Nuvothera, a Fort Worth, Texas-based biotech company, has reached agreement to have its revolutionary Prosoria Psoriasis Treatment System in select CVS HealthHUB Stores and on CVS.com.

Prosoria is an effective, over-the-counter treatment with long-lasting results for a tough-to-treat skin condition. Formulated with maximum strength ingredients, botanicals and vitamins, Prosoria effectively relieves psoriasis symptoms and is safe for daily use. The formula is steroid-free, paraben-free, and fragrance-free.

April 22, 2022

April is National Donate Life Month, and Southwest Transplant Alliance (STA), a Dallas-based nonprofit organ procurement organization serving more than 10 million Texans, invites everyone to learn more about the part they can play in saving lives this month.

Saying YES to organ and tissue donation is more than just checking a box – it’s saying yes to hope, opportunity, life and legacy. Just ONE person can save up to EIGHT lives through organ donation and impact up to 75 others through tissue donation.

To show support in registering as an organ, eye and tissue donor, wear green and blue on April 22 and participate in STA’s virtual photo booth.

April 22, 2022

Register for the webinar here.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, after the financial markets close. The company will host a conference call and webcast in a webinar format at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Tuesday, May 3, 2022.

April 19, 2022

Fort Worth-based Eosera, a biotech startup specializing in innovative ear care products, has graduated from the TechFW accelerator and business incubator—and now its co-founder and CEO Elyse Dickerson (above, with co-founder and CSO Joe Griffin) is joining the nonprofit’s board.

April 18, 2022

Taysha Gene Therapies, Inc., a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, announced its participation in the upcoming panel and fireside chat at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit. The panel discussion and fireside chat will take place on April 25, 2022.

April 12, 2022

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces the appointment of Don Kalkofen as Chief Financial Officer (CFO) to replace Jeremy Wright. Mr. Wright will continue to assist the Company in a consulting capacity.

In connection with Mr. Kalkofen’s appointment as CFO of the Company, he has been granted 450,000 stock options pursuant to the Company’s stock option plan, exercisable at a price of $0.93 CAD for a period of ten years from the date of grant, subject to certain vesting provisions.

April 12, 2022

OncoNano Medicine, Inc. today announced positive results from the company’s ON-BOARD™ pH-sensitive nanoparticle platform. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, demonstrate that the clinically validated ON-BOARD™ platform has the potential to be a universal tool for tumor specific activation and the efficient delivery of proteins for an improved therapeutic index.

April 8, 2022

NORD and the other 90 co-signing organizations believe reforms are necessary to help ensure patients have timely access to rare disease treatments that have been FDA approved through the accelerated approval pathway.

One letter is directed toward Congressional leadership urging them to incorporate into legislation to reauthorize the Prescription Drug User Fee Act (PDUFA) several policy recommendations to strengthen the accelerated approval.

Another letter is directed to HHS Secretary Becerra, urging him to support the efforts underway within Congress and FDA to strengthen the accelerated approval pathway and reject policies that could limit patient access to rare disease and other therapies that utilize accelerated approval.

April 4, 2022

Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced expansion of its Clinical and Scientific Advisory Board to include three newly appointed members.

March 31, 2022

Texas, the ninth largest economy in the world according to Gross Domestic Product (GDP), saw a 10.1% increase in the annual rate growth of real GDP in the last quarter of 2021 — compared to the national average of 6.9% — according to data from the Bureau of Economic Analysis released today, March 31.

March 31, 2022

Fort Worth-based healthcare startup AyuVis has received its second patent in three months for immunotherapy treatments that protect pre-term babies from their second leading cause of death: bronchopulmonary dysplasia (BPD), a debilitating chronic lung disease that affects many pre-term infants on ventilators.

The second patent approval from the U.S. Patent and Trademark Office specifically protects AuyVis’ lead drug candidate, AVR-48, which is scheduled for clinical trials this summer. The AVR-48 patent has also been approved in Australia and is under examination in several other international jurisdictions.

March 31, 2021

“2021 was a year of accomplishment that included positive data from three clinical programs, including GAN, GM2 gangliosidosis and CLN7 disease. We are sharpening our strategic focus to prioritize key value-driving registration-directed programs in GAN, which has an estimated addressable patient population of 5,000 worldwide, and Rett syndrome, which affects over 350,000 patients worldwide,” noted RA Session II, President, Founder and CEO of Taysha.

March 23, 2022

Texas Biomedical Research Institute has been selected by the National Institutes of Health (NIH) to host one of the nation’s inaugural training centers for tuberculosis (TB) research.

The “Interdisciplinary NexGen TB Research Advancement Center” (IN-TRAC) will harness the extensive expertise, unique facilities and collaborations based at Texas Biomed and across South Texas, including the only free-standing TB hospital in the U.S., and field research at the Texas-Mexico border. The result: a world-class training program for the next generation of TB researchers.

March 22, 2022

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its Board of Directors has authorized an extension through July 31, 2022 of Lantern's existing share repurchase program to acquire up to $7 million of the Company's common stock.

March 17, 2022

"When it comes to the biotech industry, our region is leading the U.S. in key metrics of job growth and investment," write Kathleen Otto and George Goodno. One proof point? VC funding is flowing into Dallas Fort Worth at a faster rate than any other area in the nation. These North Texas life science leaders say the region's success is no coincidence. Here is how the shared ambition of key players and strategic collaboration has impact.

March 15, 2022

The TMC Venture Fund launched in 2017 as a $25 million initiative to fill a much-needed gap in the Houston venture capital ecosystem. Since its inception, TMC Venture Fund has partnered with 16 startups, with a focus on digital health and medical device companies.

“Over the past five years, the TMC Venture Fund has been privileged to partner with extraordinary entrepreneurs to help them achieve their visions,” said John (JR) Reale, Venture Lead for the TMC Venture Fund.

March 10, 2022

Institute for Health Disparities (IHD) was founded at The University of North Texas Health Science Center at Fort Worth (UNTHSC) to advance career paths in biomedical sciences and health professions that reflect the diverse constituency we serve.

The Texas Center for Health Disparities, based at The University of North Texas Health Science Center at Fort Worth, recently was selected to participate in the national Healthy People 2030 program that focuses on decreasing inequities in health care access. 

March 10, 2022

OncoNano Medicine, Inc will present two poster presentations at the American Association for Cancer Research (AACR) Anual Meeting 2022, taking place from April 8 - 13, 2022 in New Orleans, Louisiana.

March 10, 2022

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results and operational highlights for the fourth quarter and fiscal year ended December 31, 2021.

March 10, 2022

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported important corporate events and its financial results for the full year and the fourth quarter ended December 31, 2021.

March 8, 2022

ReCode Therapeutics will present a corporate overview at the upcoming Oppenheimer 32nd Annual Healthcare Conference being held virtually from March 15-16, 2022.

Taysha Gene Therapies has announced its participation in two fireside chats at the Oppenheimer 32nd Annual Virtual Healthcare Conference on Monday, March 14, 2022, and Tuesday, March 15, 2022.

February 22, 2022

Is your life sciences company still using paper as part of your quality management system (qms)? Qualio’s all-in-one digital qms and expert advisory team helps companies launch and scale their life-saving products. Over 400 medical device, therapeutics, clinical research, and consumer goods companies leverage Qualio’s cloud qms to not only get to market faster but also unite their teams’ processes and data.

With Qualio, companies can safely scale and swiftly bridge product development and quality management - while also seamlessly achieving 100% ISO, GxP and FDA compliance and consistent audit-readiness. Qualio’s global, remote-first team prides itself on empowering customers to give patients faster access to products they can trust to improve their lives.

If your company is considering the move from a paper to digital qms, learn the steps for a successful transition. Questions? Get in touch with us here.

February 16, 2022

The Cancer Prevention and Research Institute of Texas (CPRIT) announced 74 new cancer research and prevention grants totaling over $112,768,740. The projects approved includes 65 academic research grant awards, seven prevention awards, and two product development research awards granted to 16 institutions and companies across the state.

February 15, 2022

Lantern Pharma (NASDAQ: LTRN), a Dallas-based clinical stage biopharmaceutical company using its proprietary artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it is expanding opportunities for its portfolio of drug candidates and A.I. drug discovery platform into additional rare pediatric cancers through a collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at the University of Texas Health Science Center at San Antonio (UTHSCSA).

February 13, 2022

AyuVis Research, which is developing a series of immune therapies that can prevent and treat a variety of inflammatory and infectious diseases, has been granted its first Composition of Matter patent from the U.S. Patent and Trademark Office.

February 11, 2022

Dr. Heather Hayenga, assistant professor of bioengineering, turned her focus from cardiovascular disease to solving the genetic engineering puzzle behind her rare form of cancer after she was diagnosed. She then enlisted her colleagues in the Erik Jonsson School of Engineering and Computer Science to help her research.

February 9, 2022

Taysha Gene Therapies, Inc., a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the presentation of clinical safety data supporting the first-generation construct at the highest dose of 1.0x1015 total vg for the treatment of CLN7 Batten disease at the 18th Annual WORLD Symposium, held February 7-11, 2022, by investigators from UT Southwestern.

January 25, 2022

Nanoscope Therapeutics Inc. has received IND clearance from the Food & Drug Administration (FDA) to begin a Phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients.

January 24, 2022

Today Dallas-based seed accelerator, Health Wildcatters announced that the accelerator will be moving its headquarters to the newly renovated Pegasus Park Campus located at 3000 Pegasus Park Drive, in the summer of 2022. Health Wildcatters has been at their current space in Downtown Dallas for just under six years.

January 19, 2022

NIIMBL will host a virtual internship, career, and job fair on February 8 - 10, 2022 with a targeted sessions for internships & co-ops, entry level talent, and experienced professionals.

January 12, 2022

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative diseases, today announced that it has been named winner in the “Biotech Innovation” category at the D CEO and Dallas Innovates third annual 2022 Innovation Awards, which honors disruptors and trailblazers contributing to the North Texas Hi-Tech corridor.

January 11, 2022

Last Mile Education Fund announced today the North Texas Biotech Workforce Fund, a $100,000 regional fund in support of students pursuing biotech and related STEM degrees in 26 designated North Texas counties. Through this first-of-its-kind fund, Last Mile Education Fund is increasing access to biotech careers for low-income North Texas students who can rapidly join the burgeoning biotech workforce.

January 12, 2022

Lantern Pharma has expanded their collaboration with Developmental Therapeutics Branch of the NCI. The expansion of this collaboration follows the identification of several gene signatures that predicted a potential response of a patient's tumor to Lantern's drug candidates.

January 11, 2022

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced a definitive agreement with DeuteRx, LLC to acquire an oral, small molecule targeted protein degradation portfolio. The acquisition includes a lead drug candidate that Salarius has renamed SP-3164 (formerly DRX-164), the related patent family, including issued composition of matter patents, and the opportunity to develop additional undisclosed cancer-fighting assets in the targeted protein degradation space. Targeted protein degradation takes advantage of the body’s own degradation system to promote the selective elimination of disease-causing proteins.

January 10, 2022

Nanoscope has been awarded a U.S. patent protecting its Multi-Characteristic Opsin (MCO) optogenetic gene therapy for restoring vision.

December 17, 2021

DFW, TX – BioNORTHTEXAS (BioNTX) announced today that John Q. Adams Sr. was presented with the 2021 Dennis Stone Award in recognition of his leadership and commitment to strengthening the biotechnology and public health sectors within the North Texas region.

Mr. Adams received the award at the 2021 iC3 Life Science Summit. During Mr. Adams’ career as a leader in the pharmaceutical industry, he has owned three companies: Baylor Laboratories, Allerderm, Inc., and Adams Laboratories. All three companies achieved successful exit through acquisition. Mr. Adams later repurchased Adams Laboratories and served as its Chairman and Chief Executive Officer until October 2005.

“As an early pioneer of our regions rapidly growing biopharma industry, John Q. Adams Sr. established himself as an entrepreneur and skilled executive leader of numerous companies developing innovations to benefit patients,” said Kathleen Otto,

Chief Executive Officer of BioNTX. “We thank John for his outstanding leadership and dedication to medical innovation. We were honored to present him this award."

December 8, 2021

Evolve Biologics® Announces Site Selection, Land Purchase and Groundbreaking Ceremony for First Manufacturing Facility in Sachse, Texas

New state-of-the-art commercial facility will be the first to use Evolve’s innovative PlasmaCap EBA® technology to produce plasma-derived therapeutics. Site selection and land purchase mark achievement of another significant milestone as Company continues towards the commercialization of plasma-derived therapeutics

MISSISSAUGA, Ontario, December 06, 2021--(BUSINESS WIRE)--Evolve Biologics Inc. ("Evolve"), an innovative plasma-derived therapeutics company, today announced the site selection, land purchase and groundbreaking ceremony for its first manufacturing facility in Sachse, Texas. This state-of-the-art facility will be the first to use Evolve’s innovative and proprietary technology, PlasmaCap EBA®, to commercially produce plasma-derived therapeutics, initially Intravenous Immunoglobulin (IVIG) and Human Serum Albumin (HSA).

November 4, 2021

UT Southwestern Medical Center has been selected as a Rare Disease Center of Excellence – charter members of an elite network of 31 centers nationally to expand access, and advance care and research for rare disease patients in the United States.

October 27, 2021

J.D. was only 3 months old when the lump appeared on his abdomen last year. An ultrasound showed seven lesions on the baby’s liver. Doctors told Dr. Shashank Sirsi, assistant professor of bioengineering at The University of Texas at Dallas, and his wife, Dr. Priya Joshi, a Dallas physician, that their son’s lesions were not necessarily abnormal. However, more tests revealed that J.D. had neuroblastoma, a cancer that starts in immature nerve cells. The disease affects 700 to 800 children each year, according to the American Cancer Society.

June 2, 2021

Bio North Texas Foundation (BioNTX) today announced that its Board of Directors have named Jason Wietjes as President and Chair. The organization represents the bioscience industry in North Texas and is affiliated with the Texas Bioscience and Healthcare Institute in Austin and the Biotechnology Innovation Organization in Washington DC, the worldwide advocate of the Biotech industry.

May 27, 2021

Bio North Texas Foundation (BioNTX) today announced the appointment of Kathleen M. Otto as Chief Executive Officer. The organization represents the bioscience industry for 26 counties in North Texas including Dallas, Fort Worth, and Arlington. Former CEO and Chairman Jorge Varela will continue serving on the Board of Directors of the organization.

October 12, 2020

Bio North Texas Foundation announced today the 2020 iC3® Rising Star Recipients. iC3® Rising Stars spotlight North Texas based companies that have demonstrated the potential to improve the quality of life through a healthier community and through economic growth. These are companies that are representative of the thriving North Texas life sciences community.